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SUMMARY
Induction of the cytochrome P-450 mixed-function oxidase and 
specifically the cytochrome P-450 IVA1 isoenzyme by seven phenoxy 
acid herbicides in rat liver and kidney, have been studied. 
results using liver microsomes demonstrated that the 12- 
hydroxylation of lauric acid was significantly induced by all 
compounds (3 - 8-fold), 4-chlorophenoxyacetic acid (CPA) (300 
mg/kg) being the weakest and 2,4,5-trichlorophenoxypropionic acid 
(2,4,5-TP) (200 mg/kg) the most potent inducers respectively. This 
increase in lauric acid 12-hydroxylase-activity was accompanied by 
an increase in the hepatic content of cytochrome P-450 IVA1 as 
assessed by both a qualitative Western blot procedure and a 
quantitative ELISA method. Furthermore, there was a parallel 
increase in cytochrome P-450 IVA1 mRNA and a similar increase in 
peroxisomal ^-oxidation subsequent to exposure to these compounds. 
In addition, benzphetamine-N-demethylase, a marker of cytochrome P- 
450 IIBl and IIB2 activities, was not affected by any of the 
herbicides, whereas cytochrome P-450 IA1 and IA2, as assayed by 
ethoxyresorufin-O-deethylase activity, was significantly increased 
(up to 2.2-fold) by some of the compounds. Kidney microsomal
parameters were not affected by any of these compounds.
My ini vivo studies using antipyrine, pentobarbital and 
zoxazolamine indicated that the metabolism of these substrates was 
marginally affected by only some of the compounds.
In order to highlight the possible involvement of a metabolite 
of the chlorophenoxy acids in the induction of cytochrome P-450, I 
investigated four related chlorophenols. There was no significant 
change in cytochrome P-450 isoenzyme levels in rat liver and kidney 
microsomes nor was there any increase in peroxisomal JB-oxidation.
Taken collectively, the results presented in this thesis 
indicate that the chlorinated phenoxy acid herbicides studied 
preferentially induce the cytochrome P-450 IVA1 isoenzyme and 
peroxisomal ^ 3-oxidation in a pattern similar to the typical inducers 
of this isoenzyme such as clofibrate. A scheme is presented whereby 
induction of catalytically competent cytochrome P-450 IVA1 is 
required for the phenomenon of peroxisome proliferation by these 
chlorophenoxy acid derivatives.
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ABBREVIATIONS
Abs absorbance
Ah aryl hydrocarbon
ATP adenosine triphosphate
BSA bovine serum albumin
cDNA complimentary ENA
CP 4-chlorophenol
CPA 4-chlorophenoxyacetic acid
CTP cytidine triphosphate
2,4-D 2,4-dichlorophenoxyacetic acid
2,4-DB 2,4-dichlorophenoxybutyric acid
DCP 2,4-dichlorophenol
ENA deoxyribonucleic acid
ENB 5,5*-dithiobis (2-nitrobenzoic acid)
2,4-DP 2,4-dichlorophenoxypropionic acid
EOT dithiothreitol
EDTA ethylenediaminetetraacetic acid
ELISA enzyme linked immunosorbent assay
FAD flavin adenine dinucleotide
FADH reduced FAD
GTP guanosine triphosphate
HEPES N-2-hydroxyethyIpiperazine-N1 -2-ethanesulfonic acid
HMA 3-hydroxy-^methyl-antipyrine
HPLC high pressure liquid chranatography
3-M3 3-methylcholanthrene
MCP 4-chloro-(2-methyl)-phenol
NCPA 4-chloro-(2-methyl)-phenoxyacetic acid
mRNA messenger RNA
NAD nicotinamide adenine dinucleotide
NADH reduced NAD
NADPH reduced nicotinamide adenine dinucleotide phosphate
NORA norantipyrine
OBA 4-hydroxyantipyrine
PBS phosphate buffered saline
PBSGT PBS containing gelatine and Tween 20
PPbP peroxisome proliferator binding protein
pna ribonucleic acid
SDS-PAGE sodium dodecylsulphate polyacrylamide gel 
electrophoresis
SSC sodium citrate, sodium chloride solution
2,4,5-T 2,4,5-trichlorophenoxyacetic acid
TCDD 2,3,7,8-tetrachlorodibenzo-p-dioxin
TCP 2,4,5-trichlorophenol
TEMED N ,N-tetramethylethylethylenediamine
2,4,5-TP 2,4,5-trichlorophenoxypropionic acid
TTP thymidine triphosphate
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CHAPTER ONE
INTRODUCTION
CHAPTER 1
INffiODDCTIGN
Enzyme induction plays an important role in normal development 
and differentiation of the cell; in the regulation of essential 
metabolic pathways, in the cellular action of various hormones and 
in the response of mammals to drugs and other lipophilic xenobiotics 
(Gelehrter, 1976). It is now many years since Brown et al (1954) 
noticed the stimulatory effect of foreign compounds on liver 
microsomal enzymes, in particular the dietary factors that influence 
the activity of hepatic aminoazo dye-N-demethylase.
Further studies revealed that administration of small doses of 
polycyclic aromatic hydrocarbons, such as 3-methylcholanthrene, 
increased several-fold the activities of the liver microsomal 
enzymes which are able to oxidise and reduce a variety of functional 
groups in drugs and other xenobiotics (Conney, 1967). Furthermore, 
it was found that the activity of enzymes which catalyze the 
covalent binding of aminoazo dyes to proteins, was also enhanced by 
co-administration of polyaromatic hydrocarbons. Barbiturates, among 
other drugs, was discovered to stimulate liver microsomal drug 
metabolism (Lu and West, 1980). These early observations inspired 
an intense research effort over the ensuing years into the nature of 
the enzyme(s) induced, the molecular characteristic of enzyme- 
inducing agents and the molecular mechanisms of enzyme induction.
Drugs are metabolised by a number of enzyme systems which, 
collectively appear to have the ability to interact with an 
unlimited number of organic chemicals. Studies in animals, 
demonstrating sex and strain differences and genetic polymorphism, 
illustrate the ever-increasing awareness of the complexities of 
cytochrome P-450 enzymes, and other enzymes involved in reduction, 
hydrolysis and conjugation of endogenous and exogenous compounds (Lu 
and West, 1980). Many different forms of cytochrome P-450 have now 
been isolated and characterised from many animal species and man. 
Most of these forms have been isolated from animals treated with 
inducing agents such as phenobarbitone, and 3-methylcholanthrene 
(Nebert et al., 1987), and each of these agents induces several 
forms of cytochrome P-450.
1.1 HEPATOMEGALY
Hepatomegaly is liver enlargement measured as an increase in 
the liver-to-body weight ratio, and it appears to be a 
characteristic response in laboratory animals exposed to a variety 
of xenobiotics (Reddy and Lalwani, 1983). This enlargement may be 
associated with an increase in the number and size of peroxisomes, 
and in the accumulation of lipid droplets (Hawkins et al., 1987). 
The administration of hypolipidaemic agents and chlorinated 
phenoxyacids to rodents is predictably associated with hepatomegaly, 
the extent of which is dependent upon the agent involved (Lake et 
al. 1975, Reddy 1980, Kawashima et al. 1983 and 1984a & b, Foumel 
et al. 1985). The nature of the hepatomegalic effect produced by 
clofibrate in the rat was initially studied by Hess et air, (1965).
3A daily oral dose for a period of 14 days resulted in a significant 
enlargement of the liver. The relative weight increased rapidly 
during the first week and fell to permanent levels after withdrawal 
of clofibrate at 22-30 days. Liver enlargement has been observed in 
both male and female rats, and this has been attributed, in part, to 
an increase in phospholipid and total protein levels (Azamoff et 
al., 1965). An associated increase in microsomal and cell sap 
protein concentration has also been noted (Platt and Cockrill, 
1969).
It has been established that the liver enlargement induced by 
clofibrate and nafenopin is the result of hypertrophy and 
hyperplasia, which may be dependent on the dose and duration of 
treatment (Beckett et al., 1972). A marked increase in cell size 
was observed in centrilobular hepatocytes and the increase in cell 
number correlated with increases in hepatic DNA content in 
nafenopin-treated animals (Beckett et al., 1972). The nafenopin- 
induced hepatomegaly may be attributed to hypertrophy associated 
with a marked proliferation of the smooth endoplasmic reticulum and 
peroxisomes (Reddy et al., 1973). Chronic administration of
nefenopin and clofibrate results in an accumulation of protein, 
phospholipids and RNA, with the absence of cholesterol or 
triglycerides, indicating an adaptive hepatomegaly opposed to a 
pathological condition associated with fat droplets and high 
cholesterol and/or triglycerides levels (Dalton et al., 1974).
Wy-14,643-induced liver enlargement is attributed to 
hypertrophy and hyperplasia (Reddy et al., 1979). Short-term 
administration of this compound stimulates DNA replication and cell 
division. Administration of bezafibrate for 5 days causes a marked 
hepatic enlargement associated with an alteration of the mixed- 
function oxidase system (Facino and Carini, 1981). Chronic 
administration of fenofibrate, methyl clofenapate, and fibric acid 
results in a dose-dependent increase in liver size of a comparable 
magnitude markedly greater than the clofibrate-treated group (Orton 
and Parker, 1982).
2,4,5-T treatment of rats produced hepatomegaly at lesser 
magnitude than that produced by clofibrate (Kawashima et al., 1984a) 
whereas 2,4-D treatment did not cause hepatomegaly, linking the 
hepatomegaly-induced to the induction of peroxisomal B-oxidation 
enzymes by clofibrate and 2,4,5-T.
It would appear that administration of hypolipidaemic agents 
characteristically results in a hepatomegaly of a hypertropic and 
hyperplastic nature. Hypertrophy may be associated with a combined 
proliferation of the smooth endoplasmic reticulumand peroxisomes, 
and in some instances a contributory increase in mitochondrial 
number (Hess et al., 1965). However, induction of peroxisomal B- 
oxidation dissociated from hepatomegaly and peroxisome proliferation 
has been reported with bezafibrate, indicative that hepatomegaly is 
dose-dependent and may or may not reflect ultrastructural changes 
(Lazarow et al., 1982).
1.2 Cytochrome P-450 IA1 and 2 induction
As a result of intensive studies on the metabolic fate of 
xenobiotics in animals, it is now recognised that many chemical 
carcinogens are not active per se, but require bio transformation to 
reactive species, which are ultimately recognisable for the 
initiation of tumorigenic processes. The membrane bound cytochrome 
P-450 system has been shown to play a central role in the activation 
of such potent carcinogens as hydrazine derivatives, nitrosamines, 
aromatic amines, and polcyclic aromatic hydrocarbons (for review see 
Miller 1978, Guengerich et al., 1985, Parke 1987).
Arylamine activation is postulated to be catalysed most 
efficiently in rats by hepatic cytochrome P-450 IA1 and IA2 
isoenzymes and their orthologues in other tissues and species; 
Thomas et al., 1982, Masson et al., 1983,Yamazoe et al., 1984.
Several forms of cytochrome P-450 have been purified from rat 
liver microsomes (for review see Lu and West 1980, Giuengerich 1987, 
Nebert 1987) and can now be quantified individually using specific 
antibodies. Using this approach it has been shown that a number of 
xenobiotics each induce several different isoenzymes of cytochrome 
P-450. For example, treatment of animals with 2,3,7,8- 
tetrachlorodibenzo-P-dioxin (TCDD), 3-methylcholanthrene, isosafrole 
or certain polyhalogenated biphenyls increases the level of both 
cytochromes P-450 IA 1 and 2 (c and d), but to different extents 
(Thomas et al 1983, Parkinson et al 1983, Dannan et al 1983). 
Although the molecular mechanism of induction is still far from
clear, the induction of cytochrome P-450 IA1 seems to be mediated by 
a cytoplasmic receptor with high affinity for TCDD, 3- 
methylcholanthrene, yB-naphthoflavone and some polychlorinated 
biphenyls, all bind to the same receptor with different affinities 
(Bandira et al 1982, Poland and Glover 1976). Thus, it is generally 
accepted today that TCDD is a true inducer of some drug-metabolising 
enzymes.
It is now well-known that many toxic chemicals are 
metabolically converted into reactive species by the action of 
microsomal mixed-function oxidases (Ioannides and Parke, 1980). This 
enzyme system requires oxygen and reduced NADPH and comprises 
cytochrome P-450 reductase and the haemoprotein cytochrome P-450 
acting as the terminal oxygenase (Cooper et al, 1965; Phillipson et 
al 1982). Cytochrome P-450 IA is preferentially induced by many 
carcinogens and is also involved in their activation (Ioannides et 
al 1981, 1984), as well as in the activation of certain drugs such 
as paracetamol to reactive metabolites responsible for their 
toxicity (Ioannides et al 1983, Steel et al 1983). The activity of 
cytochrome P-450 IA1 may be determined using substrate and reactions 
which are exclusively catalysed by this form of cytochrome, such as 
2-hydroxylation of biphenyl, the O-deethylation of 
ethoxyresorufin,EROD, (Burke and Mayer 1975) and the activation of 
benzo[a]pyrene to mutagens (Ioannides et al 1981, Phillipson 1985). 
An excellent direct correlation has been observed between EROD and 
metabolic activation of benzo[a]pyrene to mutagens.
7The possibility of the presence of trace amounts of TCDD and 
similar compounds in the chlorinated phenoxy acids cannot be ruled 
out since this compound can be formed from 2,4,5-TCP or similar 
phenolic compounds. During the past three decades, halogenated 
aromatic hydrocarbons such as polychlorinated biphenyls and dioxins 
have generated intense public and scientific concern because of 
their widespread occurrence as environmental contaminants, their 
resistance to degradation, and their biological potency. The 
prototypical halogenated aromatic hydrocarbon, TCDD, produces a 
diverse set of responses in experimental animals, inducing a wasting 
syndrome, immunological alteration, -teratogenic effects, tumor 
promotion, epithelial hyperplasia /metaplasia, and the induction of 
several drug metabolising enzymes (Poland and Knutson, 1982). In 
many cell types, TCDD induces the activity of aryl hydrocarbon 
hydroxylase (AHH) many times greater than that of 3MC and 
naphthoflavone (Poland and Glover, 1976), which is primarily 
catalysed by an isoenzyme of cytochrome P-450, cytochrome P-450 IA1 
in rat (Whitlock, 1986). The AHH system is responsible for the 
metabolic activities and detoxification of polycyclic aromatic 
hydrocarbons (Gelboin, 1980) and TCDD is the best inducer of AHH 
activity. TCDD induces the AHH activity by increasing the rate of 
transcription of the cytochrome P-450 IA1 gene (Israel and Whitlock 
1984), by means of binding to a receptor with properties similar to 
the steroid receptor (Wilhelmsson et al 1986) and differ in their 
ligand binding domain, because steroids do not bind TCDD receptors, 
nor does TCDD bind to steroid receptors (Poellinger et al 1983). 
The binding of TCDD to the receptor results in the formation of
TCDD-receptor complex (Israel and Whitlock, 1989) which is a DNA- 
binding protein (Hannah et al 1986., Darrin et al 1987).
1.3 Cytochronie P-450 IVA1 induction
Recent work from this laboratory has shown that pre-treatment 
of rats with the hypolipidaemic drug clofibrate resulted in a 
significant increase in the w-and (w-l)-hydroxylation of lauric acid 
- the former pathway being preferentially induced (Gibson et al 
1982). Not only does clofibrate pretreatment increase fatty acid 
oxidation, but a specific isoenzyme of cytochrome P-450 (P-450 IVA1) 
is induced by this hypolipidaemic agent. Cytochrome P-450 IVA1 has 
been subsequently purified to electrophoretic homogenity from 
clofibrate-treated rat liver and the protein biochemistry of the 
enzyme described in detail (Tamburini et al 1984). Comparison of the 
highly purified cytochrome P-450 IVA1 with other drug-induced 
cytochrome P-450s (phenobarbital and /B-naphthoflavone) has 
uniquivocally shown that cytochrome P-450 IVA1 has unique 
properties, one of which is high substrate specificity for the w- 
oxidation of lauric acid (Tamburini et al 1984, Bains et al 1985). a 
specificity not usually observed in the cytochrome P-450 group of 
hepatic enzymes. Furthermore, a specific polyclonal antibody raised 
against clofibrate-induced purified cytochrome P-450 IVA1 in sheep 
recognised its homologous antigen but did not cross-react with 
purified cytochrome P-450 isoenzymes induced by either PB or yB- 
naphthoflavone (Tamburini et al 1984). These antibodies recognised 
a single protein of the correct molecular weight (51,500)for 
cytochrome P-450 IVA1 in Western blot procedure (Sharma et al 1988a)
9and gave one reactive spot in 2-D electrophoresis, viz. 
electrofocusing followed by SDS-page (Gibson, G.G. personal 
communication). It should be noted that the precise mechanism of 
cytochrome P-450 IVA1 induction still remains speculative in that a 
cytosolic receptor mediating induction has been proposed (Lalwani et 
al 1983). A clofibrate-binding protein or receptor of molecular 
weight of 70000 was purified with very low affinity towards 
clofibrate (Lalwani et al., 1983, 1987).
Recently Milton et al (1988) demonstrated the lack of 
detectable specific binding of hypolipidaemic drugs to hepatic 
homogenates (receptor) and therefore cast considerable doubt on the 
existence of such a receptor. They indicated that the peroxisome 
proliferating hypolipidaemic drugs bind to serum albumin and 
possibly to other cellular proteins not involved in the activation 
of genes necessary for peroxisome proliferation. These findings 
support a previous result (Chatterjee et al 1987) that concluded, 
using a cDNA probe to the peroxisomal bifunctional /3-oxidation 
enzyme, that proliferation is inconsistent with a receptor- mediated 
mechanism. Whether hypolipidaemic agents,, such as clofibrate, act 
via a cytosolic receptor or directly influence cytochrome P-450 IVA1 
gene regulation is still debatable, but it is abundantly clear that 
this class of compounds regulate the transcriptional activation of 
the cytochrome P-450 IVA1 gene (Hardwick et al 1987, Gonzalez 1989).
As reviewed by Reddy and Lalwani (1983) and Hawkins et al., 
(1987) clofibrate and related drugs produce three characteristic
10
liver changes in rodents; namely, proliferation of the endoplasmic 
reticulum, peroxisomal proliferation and hepatocellular carcinomas 
on chronic exposure. All the evidence indicates a coupling between 
the proliferation of peroxisomes and the endoplasmic reticulum (in 
particular the induction of cytochrome P-450 IVA1) with high 
correlation between some of the enzymes involved (Sharma et al 1988 
a & b; Gibson and Sharma 1988).
Sharma et al (1988a) presented a scheme (Fig. 1,1) whereby the 
hypolipidaemic agent (such as clofibrate) is taken up by the 
hepatocytes and induces cytochrome P-450 IVA1 synthesis. This 
induction of cytochrome P-450 IVA1 results in the increased w- 
hydroxylation of fatty acids (medium and long-chain) and is further 
metabolised through the cytosolic oxidation to long-chain 
dicarboxylic acids. These latter compounds are then taken up by the 
peroxisome thus presenting this organelle with a substrate overload 
of one of its preferred substrate (Singh et al 1984), since the 
mitochondria cannot readily metabolise long-chain fatty acids, 
(Alexon and Cannon 1984).
Bains et al (1985) demonstrated the presence of cytochrome P- 
450 IVAl in uninduced rat liver microsomes at a level which can be 
elevated several fold as a result of clofibrate treatment. It has 
also been established that the profile of arachidonic acid 
metabolites from clofibrate-treated rats is markedly different to 
that of control animals. Furthermore, Capdevila et al (1985) 
demonstrated that pre-treatment of rats with the fibric acid type
11
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hypolipidaemic drug, ciprofibrate, results in a 7-fold stimulation 
of w-and (w-l)-hydroxylation of arachidonic acid. These results 
suggest that the main function of cytochrome P-450 IVA1 is in the 
hepatic metabolism of endogenous substrates, namely fatty acids - 
for example, arachidonic acid. The use of lauric acid in the study 
of cytochrome P-450 IVA1 is because of its availability, stability 
and the limited resulting metabolites.
The metabolism of arachidonic acid (AA) by rat hepatic 
microsomes in the presence of NADPH and oxygen was reported by 
Capdevila et al (1981). Studies using various inhibitors indicated 
that metabolism of arachidonic acid to hydroxy derivatives was by a 
lipoxygenase-like function of the membrane bound cytochrome P-450. 
The involvement of cytochrome P-450 in the metabolism of AA to a 
variety of products including 19- and 20-hydroxy derivatives, has 
been established (Oliw and Oates, 1981). Further investigation led 
to the identification of several new metabolites from hepatic 
microsomal metabolism of AA including four novel epoxy acid 
derivatives (Chacos et al 1982), hydroxyicosatetraenoic acids 
(HETES), (Capdevila et al 1982), four epoxide intermediates (Oliw et 
al 1982) and epoxyeicosatrienoic acids (Chacos et al 1983a). It has 
been demonstrated that the hepatic metabolism of docosahexaenoic 
acid, presumably by the cytochrome-P-450 mono-oxygenases, results in 
the formation of 19,20-, 16, 17, 13, 14-, 10, 11- and 7,8-
dihydroxydocosapentaenoic -acids, 22-hydroxydocosahexaenoic acid and 
21-hydroxydocosahexanoic acid (Van Rollins et al 1984). In addition 
5- and 8-HETE metabolites of arachidonic acid have been isolated
(Falck et al 1984). The metabolism of leukotriene B4 by rat liver 
microsomes in the presence of oxygen and NADPH and in a
reconstituted system with cytochrome P-450 LM2, has been reported 
(Bosterling and Trudill 1983). The metabolism of arachidonic acid 
and the formation of, and biological actions of epoxygenase-derived 
eicosanoids has been reviewed recently by Fitzpatrick and Murphy 
(1989).
The involvement of cytochrome P-450 IVA1 in the omega- 
hydroxylation of saturated fatty acids has been established and it 
has been unequivocally demonstrated with the same isoenzyme 
hydroxylates arachidonic acid (Bains et al., 1985). It is plausible 
that the isoenzyme cytochrome P-450 IVA1 with omega-hydroxylase
activity is capable on the basis of broad substrate specificity of
metabolising other endogenous substrates such as saturated and
unsaturated medium to long-chain fatty acids. The elucidation of the 
precise substrate specificity is of fundamental importance in 
clarifying the physiological role of this induced haemoprotein.
14
1.4 Peroxisome proliferation and associated enzymes
Two structured classes of hypolipidaemic agents have been 
identified as inducers of peroxisomal proliferators; clofibrate and 
its structural analogous (fig.1.2) and compounds structurally 
unrelated to clofibrate such as the phthalate ester plasticisers. 
In this section, the chlorinated phenoxyacid herbicides (fig.1.3), 
structurally related to clofibrate, will be considered with 
clofibrate and other inducers of peroxisomal proliferation.
There are a large number of lipid classes, each having a 
unique anabolic and catabolic pathway. Since fatty acids are the 
structural components of the simple and complex lipids,I will 
discuss only certain aspects of their catabolism with particular 
emphasis on the /B-oxidation of medium and long chain fatty acids. 
Fatty acids are found mostly esterified, e.g. acylglycerols and 
phosphoacylglycerols. Once released from the ester linkage by the 
action of lipases, the free fatty acids can be further degraded to 
provide carbon and/or energy or be re-utilized in the biosynthesis 
of various lipids.
At the turn of the century, Knoop (1905) established that the
aliphatic hydrocarbon chains of fatty acids are degraded by the
sequential removal of two carbon units (CH3COO""), proceeding from
the carboxyl end of the molecule. This is termed the process of /£-
oxidation, signifying that each round of chemistry involves the
&
oxidation of the JB carbon prior to bond cleavage between C-C at the 
<x
C-C-COO terminals.
15
Figure 1 . 2  Hypolipidaemic Agents
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The biochemical details of the fatty acid JB-oxidation process, 
involving intermediates, sequence of conversion, enzymes and 
coenzymes were unravelled about fifty years later.
The conversion of saturated fatty acids to mono-unsaturated 
fatty acids is catalysed by a microsomal desaturation system, 
composed of reduced (NADH)-cytochrome b^ reductase, cytochrome b5 
and a terminal desaturase enzyme (cyanide-sensitive factor Shimakata 
et al 1972). For example, the terminal desaturase catalyses the 
conversion of stearoyl-CoA to oleoyl-CoA. The activity of steoroyl- 
CoA desaturase in rat liver is increased considerably by clofibric 
acid, 2-(4-chlorophenoxy)-propionic acid and 2-(4-chlorophenoxy)-2- 
methyl-propionic acid (Kawashima et al 1984b). Moreover, 2,4,5-T 
also increased the desaturase activity, although the inducing 
potency was very weak compared to that of clofibric acid. 2,4-D, 
CPA, 2-(phenoxy)-propionic acid and 2-chlorophenoxyacetic acid only 
minimally induced the desaturase activity and had no influence on 
NADH-cytochrome b5 reductase activity, cytochrome b^ content and 
terminal desaturase activity. This supports previous results 
suggesting that peroxisomal proliferators, regardless of their
structure, induce the fatty acid desaturase activity (Kawashima et 
al 1983).
Clofibric acid increased the activity of stearoyl-CoA 
desaturation in hepatic microsomes and in vivo (kawashima and Kozuka 
1982). This increase was due to the increase in the activity of 
terminal desaturase as measured by the rate constant for cytochrome 
bj reoxidation, but not due to changes in cytochrome bj content or 
NADH-cytochrome b^  reductase activity.
Peroxisomes contain many enzymes including oxidases, 
dehydrogenases, aminotransferases, reductases, hydrolases, catalase 
and the enzymes of fatty acid /3-oxidation and the glycolate cycle 
and have been identified in a variety of plant and animal tissues. 
Since the predominant reactions in peroxisomes are oxidative, the 
function of peroxisomes is geared toward the catabolic pathway, 
although some products are used as precursors in cellular anabolic 
processes.
The /3-oxidation of fatty acids and bile acid synthesis also 
occurs in peroxisomes (Lazarow 1982). The peroxisomal fatty acid /3- 
oxidation system consists of four enzyme activities: acyl-CoA
oxidase, 3-ketoacyl-CoA thiolase, enoyl-CoA hydratase, and 3- 
hydroxyacyl-CoA dehydrogenase (Lazarow 1982). The latter two enzyme 
activities are associated with a single bifunctional enzyme protein 
of molecular weight 80,000 daltons.(Reddy et al 1980, Osumi and 
Hashimoto 1979).
The administration of peroxisome proliferators to rats results 
in an increase in both peroxisome number and volume and may account 
for up to 25% (10-20 fold increase) of the hepatocyte cytoplasmic 
volume in the liver of rats and mice treated with peroxisome 
proliferators such as Wy-14,643, methylclofenapate and ciprofibrate 
(Rao and Reddy 1987). A similar magnitude of induction is seen in 
the enzymes of /3-oxidation (Reddy et al 1986) and microsomal lauric 
acid w-hydroxylase activity (Sharma et al 1988a).
2,4-D and 2,4,5-T, like clofibric acid, has been shown to 
induce peroxisomal /3-oxidation enzymes (Kawashima et al 1984a). The 
ability of 2,4,5-T to induce peroxisomal /3-oxidation was less 
pronounced than that of clofibric acid, whereas the effect of 2,4,5- 
T on peroxisomal enzymes was greater than that of 2,4-D. Most of 
the peroxisome proliferators are known to cause hepatomegaly and a 
small induction of catalase as well as of peroxisomal /3-oxida‘tion 
and carnitine acetyl transferase (Hawkins et al 1987). 2,4,5-T pre­
treatment results in hepatomegaly and induction of peroxisomal /3- 
oxidation and carnitine acetyl transferase activity (Kawashima et al 
1984a). However, 2,4-D differed from 2,4,5-T in not causing 
hepatomegaly. Lazarow et al (1982) pointed out that an increase in 
the activity of peroxisomal /3-oxidation is not always accompanied by 
an increase in catalase activity or liver size. The potency of 2,4- 
D and 2,4,5-T to induce peroxisomal enzymes may be due to their 
structural similarity to clofibric acid. However, it should be 
noted that phenoxyacetic acid, 2-chlorophenoxyacetic acid and CPA 
(4-chlorophenoxyacetic acid) hardly caused hepatomegaly or an
increase in the activity of peroxisomal /B-oxidation, catalase and 
carnitine acetyl transferase (Kawashima et al 1984a). These latter 
authors also showed that 2,4-D and 2,4,5-T treatment effectively 
increased the concentration of a polypeptide with a molecular weight 
of approximately 80,000 daltons in the light mitochondrial fraction. 
The polypeptide has been reported to be increased markedly in 
peroxisomes of livers from rats treated with peroxisome 
proliferators (Reddy and Kumar 1977).
Osumi and Hashimoto (1979) showed that a peroxisomal protein 
having activities of both enoyl-CoA hydratase and 3-hydroxyacyl-CoA 
dehydrogenase, corresponds to the above peroxisome-specific 
polypeptide with a molecular weight of 80,000 daltons. Furthermore,
2,4-D and 2,4,5-T treatment increased the activity of cyanide- 
insensitive palmitoyl-CoA oxidation, although the extent of the 
increase is less pronounced than that obtained by treatment with 
clofibric acid (Kawashima et al, 1984a), and additionally decreased 
the serum levels of triglycerides and cholesterol.
The hepatotoxicity (carcinogenicity) of chlorophenoxy acids 
and clofibrate may be due to enhanced accumulation of hydrogen 
peroxide and other oxygen-derived compounds (Reddy et al 1980, 
Vainio et al 1983), in which peroxisomal proliferation greatly 
exceeds the increase in catalase activity after exposure of rats to 
these chlorinated phenoxy compounds (Lazarow et al 1982). The 
peroxisomal proliferation may subsequently enhance the production of 
oxygen-centered reactive agents and this might be one mechanism for
the carcinogenic effects of peroxisomal proliferators such as 
clofibrate and chlorophenoxy acids (Reddy et al 1980. Hawkins et al
1987). Cytoplasmic glutathione peroxidase activity may also be of 
importance as a cellular defence mechanism (Neat et al 1980), in 
that this enzyme catalyses the oxidation of reduced glutathione and 
results in consumption of hydrogen peroxide and organic 
hydroperoxides. This enzyme activity has been reported to be 
increased after M3PA treatment (Hietanen et al 1985).
The effect of peroxisome proliferators on liver biochemistry 
parameters are rapidly reversible following the termination of
dosing. Within a few weeks of the cessation of treatment,
peroxisomal numbers, liver weight and enzyme activities return to 
control values (Reddy et al 1978, Chat ter jee et al 1983, Eacho et al
1986). This indicates the requirement of the continued presence of 
the peroxisome proliferator for the maintenance of elevated numbers 
of peroxisomes, enhanced activities of peroxisomal enzymes and the 
generation of their metabolic by-products (Stott, 1988).
The bifunctional protein of peroxisomes from rat liver 
expresses both the enoyl-CoA hydratase and 3-hydroxyacyl-CoA 
dehydrogenase enzymatic activities which form part of the fatty acid 
/3-oxidation pathway in peroxisomes as noted above (Osumi and
Hasimoto 1979). The protein is inducible, its content in
peroxisomes being increased markedly following treatment of rodents 
with peroxisome proliferators such as clofibrate (Reddy et al, 
1980).
Chatterjee et al (1987) reported that the proliferation of rat 
liver peroxisomes by the hypolipidaemic drug Wy-14,643 is associated 
with a concomitant induction of peroxisomal enzymes involved in the 
/3-oxidation of fatty acids. They concluded that the induction of 
the peroxisomal bifunctional enzyme enoyl CoA hydra tase, 3- 
hydroxylacyl-CoA dehydrogenase (ECH) activity by Wy-14,643 is due to 
an enhancement of the rate of transcription of the bifunctional 
enzyme gene and hence an increase in the enzyme mRNA, after , ten 
hours of incubating hepatocytes with Wy-14,643 in vitro. The 
relatively slow induction (10-15 hours) of the bifunctional enzyme 
mRNA in vitro (Chatterjee et al, 1989) is in striking contrast to 
the ill vivo results of Reddy et al (1986) where a maximal induction 
of the bifunctional enzyme in rat liver was detected within one hour 
of intragastric administration of the peroxisomal proliferators. 
Because of this relatively long lag period of induction, it has been 
suggested that the induction of bifunctional enzyme mRNA may involve 
an indirect effect of the drug on the transcription of this gene. 
This is in agreement with the results of Milton (1989) and Sharma et 
al (1988a) who suggested that the induction of cytochrome P-450 IVA1 
precedes the induction of /3-oxidation.
Based on iji vivo and in vitro data, Lalwani et al (1983) and 
Reddy et al (1986) proposed that hypolipidaemic drugs act through a 
receptor mechanism similar to that for steroid hormones. However, 
regulation of the genes for peroxisomal enzymes by structurally 
diverse inducing agents through a common receptor system seems 
unlikely and the evidence for the existence of such a receptor has
not been substantiated (Milton et al, 1988). Peroxisome 
proliferation is more likely to be a multistep cascade process for 
the transcriptional stimulation of the target genes of peroxisomal 
enzymes linked to the induction of cytochrome P-450 IVA1 (Sharma et 
al 1988a, Milton 1989). The cascade mechanism may be mediated 
through a feedback control and substrate induction. Conditions that 
cause accumulation of hepatocellular acyl-CoA compounds, such as a 
high-fat diet and inhibition of mitochondrial /3-oxidation, are also 
known to induce peroxisome biogenesis and peroxisomal /3-oxidation 
(Berze and Aarsland, 1985).
Dietary exposure of mice to 2,4-D and 2,4,5-T resulted in a 
substantial increase in the activities of cytosolic and microsomal 
epoxide hydrolases in mouse liver and generally less pronounced 
increases in the cytosolic glutathione transferase activity and 
microsomal content of cytochrome P-450 (Lundgren et al, 1987a & b).
2,4-D and 2,4,5-T treatment also resulted in extensive proliferation 
of peroxisomes (as judged by the total levels of carnitine 
acetyl transferase, cyanide-insensitive palmitoyl-CoA oxidation and 
catalase) and increase in total cytochrome oxidase activity whereas 
CPA treatment did not cause extensive proliferation of peroxisomes, 
but increased the specific activity of cytochrome oxidase in mouse 
liver (Lundgren et al, 1987a & b).
Recently it was reported that both microsomal and 
mitochondrial glycerol phosphate acyltransferase activities are also 
raised in liver by the administration of clofibrate (Pollard and
Brindly, 1982), indicating that clofibrate could induce not only 
peroxisomal enzymes, but also enzymes which are considered to be 
involved in lipid synthesis and are located in organelles other than 
peroxisomes.
Cultured rat hepatocytes have been suggested to be a valuable 
in vitro tool to study biochemical mechanisms of peroxisome 
proliferation and hepatotoxicity for this class of agents (Feller et 
al 1987, Lake et al 1987). Clofibric acid, ciprofibrate (Feller et 
al, 1987) and phthalate monoesters (Lake et al, 1987) increased the 
activities of laurate hydroxylase, fatty acyl-CoA oxidase, carnitine 
acetyltransferase and a polypeptide with a molecular weight of
80,000 daltons in cultured rat hepatocytes, parameters which have 
been shown to be induced in vivo in the livers of rats pre-treated 
with ciprofibrate (Hawkins et al, 1987). Furthermore, Lewis et al 
(1987) reported that like clofibrate, a number of chlorinated 
phenoxy compounds including clofibric acid, 2,4-D, 2,4-DP, 2,4-DB,
2,4,5-T and 2,4,5-TP induced cyanide-insensitive palmitoyl-CoA 
oxidation in rat hepatocytes in culture.
It has been observed, in addition to xenobiotics, that several 
nutritional and physiological states can also cause peroxisome 
proliferation in rat liver. These include high fat diets, vitamin E 
deficiency, diabetes, starvation and cold adaptation. For a review 
of this area, see Hawkins et al (1987).
1.5 In vivo induction of drug metabolism
There are 3 principal methods which can be used for the 
assessment of enzyme induction and enzyme inhibition.
1. Investigation of the pharmacokinetics of model drug
substrates in vivo. The pharmacokinetic disposition and
urinary elimination of drug and metabolites are measured 
and the concentration-time profile related to enzyme 
activity by pharmacokinetics analysis.
2. Direct measurement of enzyme activity in vitro, using 
whole tissue and/or a tissue fraction such as 
microsomes.
3. Non-invasive methods are defined as those which
do not involve administration of a test substance. 
Change of disposition of an endogenous substance, the 
formation of which is related to the activity of the 
drug-metabolising enzymes, are monitored before, during 
and after exposure to the potential inducer or 
inhibitor.
Ideally, one would like to perform parallel in vitro and in 
vivo studies in which changes in enzyme activity may be related to 
an alteration in drug disposition.
1.5.1 Clearance
For a drug to be a useful model substrate for the assessment 
of drug metabolising enzyme activity, its clearance from the body of 
the rat with the appearance of a metabolite or metabolites (e.g. in 
urine), should be directly related to the activity of the enzymes 
responsible for its metabolism. When a drug is eliminated entirely 
by metabolism, e.g. if metabolism occurs exclusively in the liver, 
then its clearance is a measure of hepatocellular enzyme activity.
For a drug that forms more than one metabolite, hepatic 
clearance will be the sum of the clearance of the individual 
metabolites. Therefore, an increase in hepatic drug-metabolising 
enzyme activity mediated by enzyme induction will increase the 
clearance of the drug. Furthermore, for a drug which undergoes 
several routes of metabolism, the increase in hepatic clearance will 
be equivalent to the sum of the increase in clearance to the 
products of the induced enzymes.
Antipyrine is a good drug to study in vivo because it exhibits 
first order elimination, entirely dependent on hepatic metabolism. 
It is absorbed rapidly and completely after oral administration, all 
routes of metabolism are known and it has no toxicological 
properties at the dose administered.
The rate of elimination of the metabolites should be rapid 
compared with its rate of formation so that metabolism is the rate- 
limiting step in the appearance of the metabolite in urine; the
metabolite excreted by the kidney entirely, the metabolite should 
not be further metabolised except to conjugates \diich can be 
hydrolysed quantitatively, and it should be produced exclusively by 
the enzymes in which one is interested.
The problems in correlating in vitro and in vivo studies of 
drug metabolism have been reviewed recently by Gillette (1984).
1.5.2. Antipyrine metabolism
Since antipyrine gained popularity in the last decade as a 
model drug for studying drug-metabolizing enzymes, the antipyrine 
test is widely used as a research tool in clinical pharmacology to 
assess the in vivo effects of numerous factors on drug metabolism in 
animals and man. Metabolite excretion is of interest for 
investigations with antipyrine. Effectively, this drug is converted 
into several Phase I metabolites, of which 4-hydroxyantipyrine, 
norantipyrine and 3-hydf oxyme thylant ipyrine are the principal 
.metabolites. Detailed investigations into the metabolism of 
antipyrine have shown that formation of these metabolites depends on 
different enzymes of the cytochrome P-450 system (Danhof et al 1979, 
Toverud et al 1981, Teunissen et al 1983, Breimer 1983).
Several studies have indicated that the three major oxidized 
metabolites of antipyrine are produced by different forms of 
cytochrome P-450 in rats, pigs and humans. In rats, a selective 
increase in the rate of OHA formation was obtained following 3- 
methylcholanthrene treatment (Danhof et al 1979, Inaba et al 1980,
Teunissen et al 1983). In pigs, OHA. is the only known metabolite 
that is formed in appreciable quantities; HMA and NORA are almost 
totally absent (Van den Broek et al 1981). In humans, induction 
studies with pentobarbital, rifampicin and antipyrine showed a 
selective increase in NORA formation (Danhof et al 1982b, Toverud et 
al 1981, Loft et al 1987).
Inhibition of antipyrine metabolism by propranolol appeared to 
be most prominent for HMA, although in some subjects clearances for 
production of NORA and OHA were also decreased (Bax et al 1981). 
Oral contraceptive steroids inhibited antipyrine metabolism non- 
selectively (Teunissen et al 1982). Boobis et al (1981) compared 
the in vivo and in vitro rates of formation of antipyrine 
metabolites in subjects with normal hepatic function and in patients 
with suspected liver disease. They found that the rank order of the 
rate of formation (clearance for production) of the three 
metabolites of antipyrine (OHA, NORA and HMA) was similar in vivo 
and in vitro (Vmax/Km). Also, there was no significant correlation 
between the relative rates of formation of any pair of antipyrine 
metabolites iji vivo and in vitro. Furthermore, these latter authors 
found a significant correlation between in vivo and in vitro rates 
of formation of each of the three metabolites in the same group of 
patients. Although these studies are indicative of the involvement 
of different forms of cytochrome P-450 in the metabolism of 
antipyrine in humans, in vitro studies with purified forms are 
ultimately needed to assess the product selectivity of the different 
forms for antipyrine. A difficulty in human in vivo studies is the 
inability to study many different inducers and substrates which have
proven to be very useful in the elucidation of the multiplicity of 
the cytochrome P-450 system in animals (Lu and West 1980, Guengrich
1987).
Using liver microsomes and purified cytochrome P-450 
isoenzymes from phenobarbital and 3-methylcholanthrene pre-treated 
rats, Buppodom et al (1986) showed that the formation of 4- 
hydroxyantipyrine was significantly increased in phenobarbital pre­
treated rats (5.4-fold) and to a lesser extent by 3- 
methylcholanthrene pre-treatment (1.7-fold), while HMA. formation was 
not enhanced at all. Recently, Loft and Poulsen (1989) and Chenery 
et al (1987), using isolated rat hepatocytes, showed that 
phenobarbital increased the formation of HMA (2.5-fold), NORA (4- 
fold) and OHA (10-fold). In hepatocytes from 3-methylcholanthrene 
pre-treated rats the Km and Vmax values for antipyrine metabolite 
formation were not significantly altered, partly in agreement with 
studies on rat liver microsomes in which unchanged NORA and OHA, but 
considerably decreased HMA formation have been observed (Kahn et al
1982). This is in contrast to previously reported results from in 
vivo studies which reported an increase in antipyrine metabolism and 
clearance of OHA and N0RA(5-10-fold) and a decrease in HMA (0.5- 
fold) after 3-methylcholanthrene administration (Danhof et al 1979, 
Teunissen et al 1983).
Aminopyrine, like antipyrine, is metabolised mainly by N- 
demethylation and hydroxylation by microsomal cytochrome P-450 
system in liver (Aust and Stevens 1971, Inoue et al 1983). The N- 
demethylation activity was attributed to the phenobarbital inducible
cytochrome P-450 (P-450IIB1 and IIB2) (Guengerich et al 1982). 
Recently, Imaoka et al (1988) showed that purified 3MC-inducible 
cytochrome P-450 (P-450 IA1 and IA2) is also involved in aminopyrine 
metabolism. It was also noted that the sex differences apply in 
that male rats have a higher catalytic activity for aminopyrine than 
female rats (Kato, 1974).
1.5.3. Barbiturate-induced sleeping time
Measuring barbiturate sleeping time and zoxazolamine paralysis 
time has been used as a rapid and simple method to obtain a rough 
estimate of both abundance and ratio of cytochrome P-450b (P-450 
IIB1) and C-type (P-450 IA1) isoenzyme activity, respectively 
(Ioannides and Parke 1973, Wiebel et al 1976. Kim and Carlson 1983). 
Also, the measurement of sleeping time and/or paralysis time in 
combination with determination of pharmacokinetic parameters has 
been reported (Buchel et al 1974 a and b, Yasata et al 1978, 
Griffeth et al 1984, Parkinson et al 1982).
The correlation in the metabolism of two related compounds - 
hexobarbital and heptobarbital - in the rat has been studied under 
conditions of a different status of induction of cytochrome P-450 
(Van der Graaff et al 1983b). A correlation with r= 0.97 was 
observed. In a subsequent study, the correlation between the 
metabolism of hexobarbital and antipyrine was addressed. 
Hexobarbital clearance is known to be increased selectively by 
phenobarbital pre-treatment. Antipyrine clearance and the formation 
of antipyrine metabolites, however, are differently affected: 3- 
methylcholanthrene increases the percentage of 4-hydroxyantipyrine,
whereas phenobarbital increases the production of 3- 
hydroxymethylantipyrine (Breimer et al 1984). A weak correlation 
between hexobarbital and antipyrine clearance was expected (r=0.08). 
However, correlation between the intrinsic clearance of hexobarbital 
and the partial clearance for production of 3- 
hydroxymethylantipyrine was excellent, with r=0.89 (Van der Graaff 
et al 1983a and 1984). Clearance data of simultaneously 
administered hexobarbital and aminopyrine also correlated well 
(r=0.92) (Van der Graaff et al 1986). For all these experiments, it 
was found that phenobarbital pre-treatment increased the clearances 
whereas 3-methylcholanthrene pre-treatment slightly reduced the 
total clearance values. Thus, it was concluded that all the 
metabolic reactions were preferentially mediated by the major 
phenobarbital-inducible cytochrome P-450 subspecies.
The in vitro metabolism of hexobarbital in the rat was studied 
using purified cytochrome P-450 IA1 and P-450 IIB1 (Miyano and Toki 
1980, Miyano et al 1980. Ryan et al 1982). Results showed that 
phenobarbital-induced cytochrome P-450 (P-450 IIB1) but not 3- 
methylcholanthrene-inducible (P-450 IA1) metabolise hexobarbital and 
benzphetamine. The latter cytochrome P-450 isoenzyme selectively 
metabolised benzo (a)pyrene, zoxazolamine and 7-ethoxycoumarine (Ryan 
et al 1982).
1.5.4. Zoxazolamine
Zoxazolamine is widely used for a pharmacologic test 
(paralysis time) that serves as a convenient indicator of changes in 
in vivo cytochrome P-450 activity in rodents (Gram et al 1967, Bums 
et al 1958 and Baird et al 1975). It is a centrally acting skeletal 
muscle relaxant of the benzazole type that inhibits reflex pathways 
within the spinal cord (Geiger et al 1958). It is partly 
metabolised to chlorzoxazone, which is used clinically to releave 
localized muscle spasm. Both compounds are centrally acting 
skeletal muscle relaxants but zoxazolamine is no longer used 
clinically due to hepa to toxicity (Smith 1965 and Franz 1975). In 
rodents and in man zoxazolamine is metabolised mainly by 3- 
methylcholanthrene-inducible cytochrome P-450 (Wiebel et al 1976 and 
Krevsky and Hitchcock 1977) and it is thought to proceed mostly via 
the 6-hydroxylation in the benzene nucleus leading to 6- 
hydroxyzoxazolamine and to a lesser extent to chlorzoxazone, \diich 
are excreted in a conjugated form in the urine (Conney et al 1960. 
Tomaszewski et al 1976, Desiraju et al 1983).
It has been demonstrated that treatment of rats with 
polycyclic aromatic hydrocarbons such as 5,6-benzoflavone and 3- 
methylcholanthrene displays increased rates of microsomal 
zoxazolamine 6-hydroxylation (Tomaszewski et al 1976). Ethanol 
pretreatment was also shown to increase zoxazolamine metabolism in 
the rat as exemplified by decreased paralysis time (Ioannides and 
Parke 1973). When hamsters were treated with ethanol or isoniazid, 
the metabolism of zoxazolamine was increased but, in contrast to
other rodent species, this drug metabolising activity was decreased 
in hamster liver microsomes after treatment with either 
phenobarbital or 5,6-benzoflavone (Ardies et al 1987). Recently, 
Van der Graaff et al (1986) studied the dose-dependent
pharmacokinetics of zoxazolamine in the rat. It was concluded that 
pharmacokinetic parameters of zoxazolamine can be used to reflect 
changes in the activity of hepatic cytochrome P-450 in the rat only 
when doses lower than 25 mg/kg are administered. Similar
studiessuggested that zoxazolamine is a more suitable agent than 
chlorzoxazone for subsequent pharmacodynamic studies of disease 
effects in rats (Yasuhara and Levy 1988). This is in support of 
previous studies which showed that model traumatic injury to rats 
caused prolonged zoxazolamine paralysis time as well as increasing 
the sleeping time caused by hexobarbital (Griffeth et al 1984). 
Such increases may be expected since that trauma was shown to 
decrease hepatic microsomal cytochrome P-450 content and activity, 
as measured by in vivo studies (Ciaccio and Francillo 1979).
Furthermore, a more detailed study demonstrated that the observed
post-traumatic decrease in hepatic cytochrome P-450 content was 
parallelled by a depression of antipyrine metabolism in vivo 
(Griffith et al 1983). Moreover, this effect was seen after a model 
injury which could be classified as only mild to moderate in 
severity and was not accompanied by histopathological changes in the 
liver or by marked serum transaminase elevation. Similar effects of 
interferons on cytochrome P-450 content and the in vitro rate of 
metabolism of benzphetamine and zoxazolamine in mice have been 
demonstrated (Parkinson et al 1982).
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1.6 Phenol metabolism
As phenols are potential metabolites of the chlorophenoxy 
acids, it is informative to discuss thair metabolism. It has been 
reported that the oxidation of benzene to phenol and phenol to 
hydroquinone is catalysed by the cytochrome P-45O-dependent mono­
oxygenase system (Gonasun et al 1973, Gollmer et al 1986). The 
haematotoxicity of benzene is not manifested by the parent compound 
(Dean 1985, Kalf 1987). The identity of the proximate toxin and/or 
leukemogen is not firmly established although it is clear that the 
primary metabolite, phenol, is not haematoxic when administered 
alone (Bruce et al 1987). It was suggested that hydroquinone and 
catechol (or the oxidized forms semiquinone and benzaquinone) or the 
reactive C(, )B-unsaturated dialdehyde muconaldehyde may be involved 
in haematotoxicity (Pellack-Walker et al 1985), Latriano et al 
1986): similar metabolites were formed after 4-chlorophenol
metabolism in rat liver (Phomchirasilp et al 1989). Furthermore, 
Eastmond et al (1987) reported that the mylotoxicity observed after 
benzene exposure could be reproduced by the coadministration of 
hydroquinone and phenol and the administration of the compounds 
individually did not elicit the toxic effects. Recently (Koop et al 
1989) identified ethanol-inducible cytochrome P-450 (P-450 IIE1) 
from rabbit liver as being the isoenzyme responsible for catalysing 
benzene and phenolbiotransformation. In this context, it should be 
noted that chlorinated benzenes induce several forms of cytochrome 
P-450 in particular, cytochrome P-450IA1, IA2 amd P-450IIB1 and IIB2 
which were induced significantly by hexachlorobenzene (Goldstein et 
al 1986).
Hesse et al (1978) and Lau et al (1984) have suggested that 
chemically reactive quinone species of catechol-derived metabolites 
of chlorobiphenols and 4-bromophenol are bound to tissue protein in 
vitro. In this regard, catechol compounds are presumed to bind to 
protein by forming highly reactive semiquinones and quinones. This 
reaction may be mediated in part by the presence of superoxide 
anions with the involvement of cytochrome P-450 (Nelson et al 1976). 
Furthermore, Phomchirasilp et al (1989) proposed that 4- 
chlorophenol may be oxidized by hepatic mixed-function oxidase 
system to a 4-chlorocatechol by a nonenzymatic rearrangement via an 
epoxide intermediate, and that 4-chlorocatechol might be further 
oxidized and converted to the corresponding semiquinone metabolites. 
This is similar to the recent finding that showed during the in 
vitro metabolism of 2,4,5-trichlorophenol by rat liver S-9 
fractions, monomeric and dimeric products were identified using gas 
chromatography-mass spectrometry (Butte et al 1988). The monomeric 
compounds were 3,4,5-trichlorocatechol and a dihydroxy- 
dichlorobenzene. A dimerization process resulted in the formation of 
a dihydroxy-hexachlorobiphenyl, a dihydroxy-pentachlorobiphenyl 
ether, two hydroxy-pentachlorobiphenyl ethers, a hydroxy-hexachloro- 
biphenyl ether and a hydroxy-hexachlorodioxin or hydroxy-hexachloro- 
diphenoquinone.
In toxicity testing, in Chinese hamster cell line V79, neither
2,4-dichlorophenol nor MCPA interfered with cell growth or 
mutagenicity, whereas 2,4-dichlorophenol only showed a dose-
dependent toxicity as well as a weak mutagenicity in a cell-mediated 
test (Fiskesjo 1988).
1.7 Conjugation
In view of the fact that the carboxyl groups of the 
chlorophenoxy acid herbicides studied are readily conjugated, this 
pathway will now be considered. Conjugation with glucuronic acid and 
sulphuric acid are most important biotrans format ions for foreign and 
endogenous compounds, and conjugation with glutathione provides a 
major defence mechanism against the toxicities produced by 
chemically reactive metabolites formed in phase I oxidation 
reactions. In rat liver, glucuronidation is catalysed by at least 
five independent forms of glucuronyl transferase: nitrophenol,
morphine, bilirubin, testosterone and esterone being representative 
substrates of different forms (Bock et al 1984) with overlapping 
substrate specificities.
Glutathione is available in liver in a high concentration, and 
any electrophilic metabolites formed in liver will undergo 
interaction with liver thiol, forming adducts resulting in a 
lowering of liver thiol content (Gillette et al 1974).
Glutathione S-transferases, which exist in multiple forms 
(Jakoby and Habig 1980) catalyse the reaction in which the 
electrophilic center of many xenobiotics is conjugated to the -SH 
group of glutathione (Chasseaud 1979, Smith and Litwack 1980). They 
are particularly abundant in liver where they can constitute up to
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10% of the total soluble fraction protein (Jakoby 1978, Boyer et al 
1983). Of these many forms of glutathione S-transferase, Vessey and 
Boyer (1984) showed that 2,4-D and 2,4,5-T inhibited forms A and C 
whereas form AA was activated by the two compounds. The microsomal 
membrane-bound form of glutathione S-transferase (form B) was also 
inhibited by 2,4-D amd 2,4,5-T. This is similar to other results 
(Dierickx 1983) who showed the mixed induction and inhibition of GST 
isoenzymes by 2,4-D in rat liver.. While GST AA isoenzyme was 
slightly stimulated by 2,4-D and MCPA, each of the other GST 
isoenzymes (A, B, C, E and M) were inhibited by 2,4-D, MCPA, 2,4-DP 
and MCPP (2-(2-methyl-4-chlorophenoxy) - propionic acid) (Dierickx
1983). The effect on GST by these compounds was by means of direct 
binding to these proteins.
Dierickx (1988) showed that 1,4-benzoquinone and 2,4-D 
inhibited cytosolic and microsomal glutathione S-transferase from 
rat liver and may therefore contribute to their toxicity, since 
glutathione S-transferase plays an important part in the 
detoxification process. In the mouse, cytosolic glutathione S- 
transferase activity was shown to be increased by 2,4-D and 2,4,5-T 
treatment (Lundgren et al 1987a & b).
Hietanen et al (1983) showed that MCPA treatment increased the 
hepatic ethoxycoumarin 0-deethylase activity by 2-fold. Both 2,4-D 
amd MCPA increased the hepatic epoxide hydrolase activity and 
decreased the hepatic glutathione S-transferase activity. UDP
glucuronosyl transferase activity was also decreased by 2,4-D and 
clofibrate.
The UDP glucuronosyl transferases are a family of membrane- 
bound enzymes which catalyse the conjugation of various endogenous 
compounds such as bilirubin and steroid hormones as well as 
exogenous chemicals and potential carcinogens, with UDP glucuronic 
acid (Dutton 1980). At least two distinctive proteins presenting 
partially overlapping substrate specificities have been described on 
the basis of their separate purification (Falany and Tephly 1983, 
Bock et al 1988), immunological properties, tissue distribution, and 
chemical structure of the conjugated aglycone (Mackenzie et al 1984, 
Boutin et al 1984). Differential regulation by inducers was 
described by Lilienblum et al (1982) and Watkins et al (1982). One 
form (G^), which metabolises planner phenols such as 4-nitrophenol 
(group I substrate), is preferentially induced by 3- 
methylcholanthrene, whereas the other form (G^) enhanced by 
phenobarbital type inducers, catalyses the conjugation of bulkier 
structures such as morphine (group II substrate) (Wishart 1978). 
Recently, Foumel et al (1985) showed a structure-dependent increase 
in glucuronidation of bibirubin after treatment of rats with CPA,
CPP and clofibric acid - the latter being the highest inducer. 
Furthermore, a close linkage was suggested between bilirubin UDP 
glucuronosyl transferase induction and that of cytochrome P-450 
IVA1, as shown by enhanced w-oxidation of lauric acid.
1.8 Renal responses to administration of peroxisome proliferators
Unlike the liver, no kidney enlargement or renal 
proliferation of the endoplasmic reticulum has been observed in ex 
perimental animals treated with hypolipidaemic agents. The major 
cellular response of the kidney to treatment is a small peroxisome 
proliferation, with a corresponding increase in peroxisome B- 
oxidation enzymes and induction of the polypeptide PPA 80,000 
(Hawkins et al., 1987).
Whereas cytochrome P-450-dependent mono-oxygenases in liver 
microsomes have been extensively studied, only a limited amount of 
information is available from studies on kidney microsomes. The 
observation that saturated fatty acids are w-hydroxylated by 
kidney microsomal preparations and that this reaction is inhibited 
by carbon monoxide (Wada et al., 1968; Ichihara et al., 1969) 
prompted Jakobsson and co-workers (1970) to examine further this 
hydroxylation system. These latter investigators demonstrated 
that rat kidney cortex microsomes catalyse the w-oxidation of 
laurate at a similar rate to that obtained with liver microsomes. 
By contrast the oxidative metabolism of aminopyrine and 
testosterone was negligible by rat kidney cortex compared to liver 
microsomes. Furthermore, Jakobsson et al., (1970) observed that 
laurate stimulated the rate of reduction of NADPH-linked 
cytochrome P-450 in kidney cortex. However, by contrast, neither 
aminopyrine nor testosterone, which are poor substrates for the 
kidney mono-oxygenase, exhibited this stimulatory activity. Of 
particular interest is the observation of feeding rats with about 
10% lauric acid in the diet stimulated in the kidney the formation
of more cytochrome P-454, increased by 4-fold the laurate 
generated type I spectral change and increased 1.5-fold the w- 
oxidation of laurate. By contrast, phenobarbital had no observable 
effect on either kidney cortex cytochrome P-454 or on the w- 
oxidation of laurate. These findings suggest that kidney and 
liver mono-oxygenases are markedly different. Subsequent studies 
from the same laboratory demonstrated that starvation of rats 
increased kidney cortex cytochrome P-454 and laurate hydroxylation 
(Ellin and Orrenius, 1971). Further investigations showed that 
the hydroxylation of laurate by rat kidney cortex microsomes 
occurs at the w- and (w-l)-positions, yielding 12-hydroxy-and 11- 
hydroxy-laurate, respectively (Ellin et al., 1972). The ratio of 
w-/(w-l)-hydroxylation of laurate remained 2:1 in a series of 
experiments with microsomes from control and from starved rats, 
though in the latter case the total hydroxylation activity was 
enhanced about 2-fold (Ellin et al., 1973). These findings may 
suggest that the hydroxylation of laurate at w- and (w-1)- 
positions in the kidney cortex is catalysed by a single enzyme.
Parker and Orton (1980) demonstrated the induction of a 
kidney microsomal cytochrome P-450 with specificity towards the 
hydroxylation of fatty acids following treatment with the 
hypolipidaemic drug, clobuzarit. Later, Imaoka and Funae (1986) 
reported the isolation of the major renal cytochrome P-450 from 
untreated rats. This protein was shown to catalyse the w-and (w- 
1) hydroxylation of lauric acid, but was inefficient in the N- 
demethylation of benzphetamine and the 0-dealkylation of 7- 
e thoxycoumarin.
Recently Sharma (1988) and Makowska (1988) showed that 
treatment of rats with clofibrate, ciprofibrate, clobuzarit, 
bezafibrate, nafenopin, DEHP, MEHP and Wy-14,643 significantly 
increased the cytochrome P-450IVA1 isoenzyme, accompanied by an 
increase in the w-hydroxylation of lauric acid and to a lesser 
extent the (w-l)-hydroxylation, but that the ethoxyresorufin-O- 
deethylase activity was significantly reduced.
Measurement of specific cytochrome P-450IVA1 by an ELISA 
technique indicated that approximately 30% of the total cytochrome 
P-450 in control kidney microsomes is immunochemically related to 
hepatic microsomal cytochrome P-450IVA1 and the level of this 
enzyme was seen to increase 2-3-fold in rat kidney after treatment 
of rats with hypolipidaemic drugs (Sharma, 1988). Furthermore, 
this increase was correlated with an increase in total lauric acid 
metabolism (3-5-fold).
The renal metabolism of fatty acids occurs either by jB- 
oxidation through the mitochondrial pathway or by w-and (w-1)- 
oxidation in the microsomal subcellular fraction. In addition, an 
extra-mitochondrial yB-oxidation pathway has also been demonstrated 
with this being located in peroxisomes in the medulla and 
medullary rays (Le Hir and Dubach, 1982).
Previous workers have reported the major cellular response 
of the kidney to treatment with hypolipidaemic agents is 
peroxisome proliferation with a corresponding increase in 
peroxisomal yB-oxidation and induction of the polypeptide PPA
80,000 molecular weight protein (Lalwani et al., 1981; Small et 
al, 1982). Other workers have reported the induction of
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mitochondrial carnitine acetyl CoA transferase in the kidney as a 
result of clofibrate treatment (Mittal and Kurup, 1981).
Peroxisome proliferation has been demonstrated in clofibrate 
treated kidney cells (Svobada et al., 1969). This proliferation 
was sex-related with male rats displaying more extensive 
peroxisome proliferation than females at the same dose levels 
(Henry and De Morrow, 1985). Induction of peroxisomal JB- 
oxidation, enoyl-CoA hydratase and PPA 80,000 with an associated 
peroxisome proliferation was reported in mouse kidney following 
methyl clofenapate, BR-931 and Wy-14,643 treatment (Lalwani et 
al., 1981).
The effect of a structurally diverse range of peroxisome 
proliferators on renal mitochondrial and peroxisomal enzymes has 
been studied in rats and other animals (Sharma, 1988; Makowska,
1988). Their results showed a 1.5-3-fold induction in peroxisomal 
^-oxidation following clofibrate, ciprofibrate, nafenopin, 
bezafibrate and DEHP treatment. A maximal 2-fold induction in 
carnitine acetyltransferase, carnitine palmitoyltransferase, total 
enoyl-CoA hydrates (mitochondrial and peroxisomal) and peroxisomal 
enoyl-CoA hydratase activities resulted from treatment (Sharma,
1988). The induction of renal enzymes was considerably lower than 
in the liver of many animals (Makowska, 1988).
1.9 Aims of the present investigation
The present study is designed to characterise the effect of 
chlorinated phenoxy acids pretreatment on the cytochrome P-450 
system and peroxisomal ^ -oxidation, in vivo and in vitro,and in 
particular cytochrome P-450IVA1 and to see if a structure 
induction relationship can be drawn and compared to existing data 
on related chemicals such as clofibrate.
CHAPTER TWO
MATERIALS AND METHODS
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CHAPTER 2 
MATERIALS AND METHODS
2.1 MATERIALS
Acetylacetone, acrylamide, Amberlite MBI resin, ammonium 
acetate, ammonium persulphate, bromophenol blue, citric acid, copper 
sulphate, EDTA, diethylpyrocarbonate, Folin phenol reagent, 
gelatine, glycine, hydrogen peroxide, magnesium chloride, potassium 
chloride, potassium cyanide, potassium phosphate, sodium 
bicarbonate, sodium carbonate, sodium chloride, sodium dithionite, 
sodium-potassium tartrate, sodium persulphite, sucrose, sodium N- 
lauryl sarcosine and Triton-X-100 were purchased from BDH Limited 
(Poole, Dorset).
Benzphetamine, acetyl CoA, bovine serum albumin, carnitine, 
Coenzyme A, 5,5'--dithiobis (2-nitrobenzoic acid), dithiothreitol, 
diaminobenzidine chloride, L-alpha-dilauryl phosphatidylcholine, 
dextran suphate, antifoam A emulsion, ethidium bromide, FAD+, 4- 
hydroquinoline, kynuramine, lauric acid, orthopheny 1-diamine, NAD+, 
NADH, NADPH, nicotinamide, MOPS (3(N-morpholino)propanesulphonic 
acid), palmitoyl CoA, pentobarbital, salmon sperm DNA (Sigma type 
III, sodium salt), sodium cholate, sodium alpha-glycerophosphate, 
sodium malonate, sodium succinate, Tris (Trizma-base), Tween 20 were 
purchased from Sigma Chemicals Company Limited (Poole, Dorset). The
herbicides 4-chlorophenol, 4-chlorophenoxy-, 2,4-dichlorophenoxy-,
2.4.5-trichlorophenoxy-, and 4-chloro-2-methylphenoxyacetic acid,
2.4-dichlorophenoxy butyric acid, 2,4-dichlorophenoxypropionic acid,
2.4.5-trichlorophenol, 2,4,5-trichlorophenoxypropionic acid and uric 
acid were also purchased from Sigma Chemicals Company Limited 
(Poole, Dorset).
Antipyrine (2,3-dimethyl-l-phenyl-3-pyrazolin-5-one,
phenazone), 4-hydroxyantipyrine, 4-dimethylaminoantipyrine, p- 
acetophenetidide (phenecetine), zoxazolamine (2-amino-5- 
chlorobenzoxazole) and the phenolics 4-chloro-2-methylphenol and
2.4-dichlorophenol were purchased from Aldrich Chemicals Company 
Limited (Dorset, UK).
Radioactive labelled (o<-P32) deoxycytidine triphosphate 
(specific activity 2000Ci/mmol) and C^-lauric acid was obtained 
from Amersham Radiochemical Centre (Amersham, Buckinghamshire); 
glycerol from Fision Scientific Equipment Company (Loughborough, 
Leicestershire); ethoxyresorufin and resorufin from Molecular Probes 
Inc. (Junction City, Oregon, USA) and the nitrocellulose filters 
(0.45 m) were purchased from Anderman and Company Limited (Kingston- 
Upon-Thames, Surrey) or from Sigma Chemical Company Limited. 
Bnulgen 911 was obtained from KAO Atlas Company (Tokyo, Japan) and 
control donkey anti-sheep IgG enzyme label was kindly supplied by 
Guildhay Antisera Limited (Guildford, Surrey).
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The ultrapure enzyme grade agarose, caesium chloride, 
guanidine hydrochloride, guanidium isothiocyanate, NACS Prepac 
colums and nick translation kits were obtained from Bethesda 
Research Laboratories (Maryland, USA).
All other chemicals were obtained as Analar grade 3 wherever 
possible, or the highest purity grade available.
2.2 METHODS
Animals; Male Wister rats (150-200g body weight) (University of 
Surrey Breeders) were used throughout the study. The rats were 
divided into groups (3 animals in each group) and were allowed free 
access to water ad libitum and laboratory food (Spratts animal diet 
No.l) and were housed in a room with 12h light/12h dark cycles and 
controlled humidity (50*5%) and temperature (21*1%). Animals were 
given daily intragastric doses of the test compounds suspended in 
peanut oil at the dose levels of 50, 100 or 200 mg/kg (MCPA and CPA 
were given as the free acid as doses of 100, 200 or 300 mg/kg) for 
three days. Control animals received corresponding quantities 
(5ml/kg) of the vehicle (peanut oil) or saline, and no significant 
differences were noted between these two control values for all 
parameters studied.
All animals were killed 24h after the last dose. The livers 
and kidneys were removed and the livers were then perfused with 
0.9%(w/v) saline prior to homogenisation. Livers were blot dried on
tissue paper and weighed. The kidneys were decapsulated before 
homogenisation. The liver and kidneys were scissor minced and 
homogenised in 0.25M sucrose (25-30% (w/v) and 15% (w/v)
respectively) using a Potter Elveham glass teflon homogeniser.
Aliquots of the homogenates were frozen at -70°C for use in 
the analysis of palmitoyl CoA ^ -oxidation and for ENA analysis.
2.3 PREPARATION OF MICROSOMAL FRACTIONS
Microsomes were prepared either by the calcium precipitation 
method, as described by Cinti et al., (1972) or by a modification of 
the ultracentrifugation method of Omura and Sato (1964).
In the calcium precipitation method liver and kidney 
homogenates in 0.25M sucrose were centrifuged at 12,600g at 4°C for 
30 minutes in 14 x 50ml rotor in a Beckman J2-21 centrifuge. After 
discarding the pellets, calcium chloride stock (80mM) was added to 
the supernatants to give a final concentration of 8iriM and this was 
then re-centrifuged at 27,400g at 4°C for 15 minutes. The resulting 
pellets were resuspended in 15ml of 0.15M potassium chloride to 
remove the CaCl and re-centrifuged at 27,400g for 15 minutes. The 
final pellets were resuspended in ice-cold 50mM potassium phosphate 
buffer (pH7.25) containing 20% (v/v) glycerol and were stored at - 
70°C until used.
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In the ultracentrifugation method, tissue homogenates in 
sucrose, after being centrifuged at 12,600g for 30 minutes at 4°C, 
the supernatants were centrifuged at 105,000g for 60 minutes at 4°C 
in a 60Ti rotor, Beckman L5-6S ultracentrifuge. The resulting 
microsomal pellets were resuspended in phosphate buffer 50mM (pH 
7.25) and stored at -70°C until used.
Microsomal protein concentration was determined by the 
modified method of Lowry et al., (1951) using bovine serum albumin 
as standard.
2.4 BHZYME ASSAYS
2.4.1 DETERMINATION OF TOTAL CYTOCHROME P-450 CONTENT
Total cytochrome P-450 was determined according to the 
spectral method of Omura and Sato (1964) using a difference 
absorption coefficient (450 to 490nm) of 91mM”^  cnT^  for the sodium 
dithionite-reduced carbon monoxide adduct. Liver microsomes were 
diluted to lmg/ml with buffer and the baseline was recorded in DW- 
2UV/VIS Varian spectrophotometer. A few grains of sodium dithionite 
were added to both cuvettes to reduce cytochrome P-450. Carbon 
monoxide was bubbled through the sample cuvette (1 bubble/second for 
30 seconds) and the reduced difference spectrum was recorded between 
500-400nm.
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For kidney microsomal cytochrome P-450 determinations, sodium 
succinate (lQmM) and NADH (25 1, 2% (w/v) solution) was included in 
the dilution buffer to reduce the cortex mitochondrial electron 
transport enzyme contamination.
2.4.2 Determination of Benzphetamine-N-Demethylase Activity
The rate of benzphetamine-N-demethylation was assessed from 
the rates of formaldehyde formation which was detected according to 
the method of Nash (1953). The incubation mixture contained 50 g/ml 
sodium deoxycholate, 15mM magnesium chloride, 50mM potassium 
phosphate buffer (pH7.25), 0.1 ml microsomal suspension
(approximately 1-2 mg protein) and 0.1 ml of 15mM benzphetamine to 
give a total volume of 1 ml. Following 2-3 minutes of incubation at 
37°C the reaction was started by the addition of 40 1 of 50mM NADPH.
After 5-10 minutes incubation at 37°C the reaction was stopped 
by the addition of 0.5ml of ice-cold 12.5% (w/v) trichloroacetic 
acid (TCA). Samples were mixed and then centrifuged at 12,000g for 
10 minutes at 4°C in a Beckman J6B centrifuge. The supernatant 
(lml) was then removed for determination of formaldehyde using the 
Nash assay.
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2.4.3 Nash Assay
Reagent: Ammonium acetate (150g) was dissolved in 900ml of
distilled water. Acetylacetone (2ml) was added and completely 
dissolved. The pH was adjusted to pH6.0 with glacial acetic acid, 
and the volume adjusted to 1 litre. The reagent was stored at 4°C.
Method: The supernatant from the TCA precipitation (1ml, Section 
2.4.2) was added to the Nash reagent (1 ml) mixed and heated in a 
water bath at 58°C for 10 minutes in the dark. After 5 minutes 
cooling, the absorbance at 412nm was recorded. A standard curve was 
plotted using 1ml volumes containing 0, 10, 20, 40, 60, 100 and 
140nmol formaldehyde and treated in an identical manner to the test 
samples. Under these conditions 1.0 A412 = 1000 nmoles formaldehyde.
2.4.4 Determination of Ethoxyresorufin-O-Deetbylase Activity
The 0-deethylation of ethoxyresorufin was routinely determined 
by the method of Burke et al., (1977), using the difference in 
fluorescent properties of ethoxyresorufin (excitation wavelength = 
456nm, emission wavelength = 586 nm) and the product resorufin 
(excitation wavelength = 510nm, emission wavelength = 586nm).
The assay system contained 30-80 ul of microsomal suspension 
in 2 ml of 0.1M Tris-HCl buffer (pH7.8) at 37°C. Ethoxyresorufin
(stock solution in methanol) was added to give a final concentration 
of 50uM. The cuvette was placed in a thermostatically controlled 
cuvette housing of a Perkin Elmer LS-5 luminescence fluorimeter, set 
at an excitation wavelength of 510nm and emission wavelength of 
586nm. After pre-incubation at 37°C for 2 minutes, a steady base­
line with time was recorded. The reaction was initiated with a 
final concnetration of ImM NADPH and the production of resorufin 
with time monitored as the increase in fluorescence at 586nm. The 
fluorimeter was calibrated with multiples of 5 and lOul of resorufin 
standard (lOuM in methanol).
2.4.5 Determination of Lauric Acid Hydroxylation
The metabolism of ^C-lauric acid to 12- and 11-hydroxylated 
products was evaluated by HPLC analysis as modified from the method 
described by Parker and Orton (1980). The incubation mixture 
contained 0.5mg or lmg protein/ml, 0.55mM -^C-lauric acid and 
O.luCi-^C-lauric acid (in methanol) in a total volume of 1.96ml. 
The tubes were incubated for 5 minutes at 37°C prior to the addition 
of 40ul NADPH (0.8mM final concentration) to initiate the reaction. 
After 5-10 minutes incubation the reaction was terminated by the 
addition of 0.2 ml of 3M HC1.
10ml of diethyl ether was then added to the incubation 
mixture, followed by mixing on a rotary shaker for 10 minutes. The
tubes were then left to stand for at least 5 minutes or centrifuged 
at 2000 rpm for 5 minutes to clarify the phases after which the 
upper ether layer was transferred to a test tube and evaporated to 
dryness under a stream of nitrogen. The test tubes were sealed with 
parafilm and stored at -70°C prior to analysis.
HFLC analysis of 11- and 12-hydroxylauric acid: The dried ether
extracts were reconstituted in 150 ml of eluting solvent, water: 
methanol: acetic acid (45:55:0.1 by volume), 50-10ul aliquots were 
then injected into the HPLC system. The metabolites of ^C-lauric 
acid were separated using a linear gradient of water:methanol:acid 
(45:55:0.1 by volume) to 100% methanol over a 35 minute period 
passing through a reverse phase ultrasphere ^-ODS column (4.6 x 
15cm) at a flow rate of lml/min. The elution profile of the 
radioactivity products was monitored using a Berthold LB 503 
radiodetector linked to a Commodore PET (Series 4000) allowing 
separate quantitation of 12- and 11-hydroxylaurate.
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2.4.6
Determination of Cyanide-Insensitive Palmitoyl-CoA ft -Oxidation
The assay was performed as described by Bronfman et al., 
(1979), as follows. A reaction mixture containing CoA (75uM),FAD 
(180uM), NAD+(555uM), nicotinamide (l41mM), DTT (4.2mM), KCN (3mM) 
and BSA (0.225mg/ml) in 60mM Tris-HCl buffer (pH8.3) was freshly 
prepared and stored on ice. A 2ml aliquot of the reaction cocktail 
and 0.96ml of 6QmM Tris-HCl buffer (pH8.3) were equilibrated at 37°C 
for 5 minutes. The liver homogenate was diluted 1.1 with 60mM Tris- 
HCl buffer (pH8.3) containing 1% (w/v) Triton-X-100 and equilibrated 
at 37°C for 2 minutes and 40ul of sample was then added to the 
cocktail buffer, transferred to a cuvette and placed in a Varian 219 
spectrophotometer. The reaction was initiated with 20ul of 75uM 
pabnitoyl-CoA and the change in absorbance at 340nm was recorded for 
10-20 minutes at 37°C. The assay measures the reduction rate of NAD+ 
to produce NADH and so the results were expressed as nmol product 
formed/min/mg protein assuming the molar absorbance coefficient of 
NADH at 340nm is 6220.
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2.5.1
QUANTITATIVE AND QUALITATIVE DETERMINATION OF CYTOCHROME P-450IVAI 
Enzyme-Linked Immunosorbent Assay (ELISA)
The quantitative studies of microsomal cytochrome P-450 IVAI 
were carried out by the ELISA technique (enzyme-linked immunosorbent 
assay) as described by Voller et al., (1978).
Antibodies raised in sheep against clofibrate-induced 
cytochrome P-450 IVAI (rat derived) were used throughout this study. 
Microsomes were solubilised in Img cholate and 0.2mg Emulgen 911 per 
mg of protein and stirred on ice for 20 minutes, diluted as 
appropriate (0.005-0.lpmoles of cytochrome P-450 per assay) with 
0.1M sodium carbonate/bicarbonate buffer (pH9.6) and coated to the 
walls of a microtitre plate at 4°C overnight in a humid environment. 
The plates were washed with phosphate-buffered saline (pH7.4) 
containing 0.1% (w/v) gelatin and 0.05% (v/v) Tween 20 (PBS-GT). 
The antisera (cytochrome P-450 IVAI antibody or the pre-immune sera 
were diluted in PBS-GT buffer as required and applied to the plates 
in 200ul volumes. The binding of the pre-immune serum to the 
cytochrome P-450 IVAI antigen was taken as the level of non-specific 
binding observed in this assay and was subtracted from the test 
immune value.
Following a 2h incubation at 37°C and washing with PBS-GT, 
donkey anti-sheep enzyme label (200ul/well) was added and incubated
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for a further 2 hours at 37°C and subsequently washed with PBS-GT. 
The substrate (100ml of 0.025M citric acid, 0.05M sodium hydrogen 
phosphate buffer, pH5.6, containing 40mg orthophenyldiamine and 40ul 
hydrogen peroxide) was added to the plates (150ul/well) and 
incubated at 37°C for 30 minutes. The reaction was terminated by 
the addition of 2.5M sulphuric acid (50ul/well). The plates were 
then read at 490nm using a Dynatech plate reader. A calibration 
curve using purified cytochrome P-450 IVAI was constructed and shown 
to be linear up to 0.02pmols of cytochrome P-450 IVAI per assay.
2.5.2 Western Blot Analysis
The method used in Western blot analysis was a modification of 
the procedures of Burnett (1981) which involves the electrophoretic 
transfer of separated proteins on polyacrylamide gel to 
nitrocellulose sheets which are then subjected to immunological 
analysis.
SDS polyacrylamide gel electrophoresis was performed on 
samples to be analysed according to the method of Laemmli (1970). 
Prior to transfer, the gels were immersed in transfer buffer (20mM 
Tris base, 150rriM glycine) for 20-30 minutes. This pre-transfer 
stage was included to allow for any swelling or shrinking in gel 
size before the transfer.
The transfer was achieved by the use of a plastic sandwich 
apparatus. A sheet of nitrocellulose paper (0.45um in pore size)
was cut to the appropriate size and laid on two sheets of Whatman 
3MM blotting paper immersed in transfer buffer. The tel to be
blotted was then laid onto the nitrocellulose sheet with two other 
sheets of blotting paper being placed on top. The whole assembly 
was then placed between two Scotch Brite scouring pads supported on 
a stiff plastic grid. It is important to ensure that no air bubbles 
are caught between the filters and the gel because of the 
possibility of low efficiency transfer and band distortion occurring 
in these areas. The immobilised assembly was then inserted into the 
electrophoretic transfer apparatus with the nitrocellulose paper 
facing the anode (+). The tank was filled with transfer buffer and 
electrophoretic transfer was achieved overnight at 5V/cm.
Following electrophoretic transfer the nitrocellulose sheet 
was washed in phosphate buffer saline (PBS) containing 1% (w/v) 
bovine serum albumin and 0.2% (v/v) Triton X-100. Washing was 
carried out for 15 minutes on a shaking water bath. After three 
washes the nitrocellulose sheet was washed for 1 hour in buffer 
containing 60ul anti-cytochrome P-450 IVAI serum.
Three further 15 minute washes with PBS wash buffer were 
followed by a second 1 hour wash with the washing buffer containing 
donkey anti-sheep (500 ul) as the second antibody. Again, 3 further 
washes in PBS wash buffer of 15 mins duration were required followed 
by a 1 hour wash with PBS wash buffer containing horseradish 
peroxidase labelled antibody (100 ul). This was washed 3 times with 
PBS wash buffer followed by one final wash with PBS alone for 15
mins. The nitrocellulose sheet was then developed in 0.1M Tris-HCl 
buffer (pH 7.5) containing 0.5 mg/ml diaminobenzidine chloride and 
1:5000 H2O2. Once the desired image intensity was observed, the 
sheet was then rinsed in distilled water which effectively stopped 
the reaction.
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2.6
ISOLATION OF TOTAL CELLULAR ENA.
Total cellular RNA was prepared from liver homogenates of 
control and treated animals according to the method of Chomczynski 
and Sacchi (1987).
Reagents
Denaturing solution (Solution D)
4M guanidium thiocyanate 
2.5mM sodium citrate, pH7.0 
0.5% (w/v) sarcosyl 
0.1, 2-mercaptoethanol
Phenol (nucleic acid grade) saturated with water
2.6.1 Experimental Procedure
One gram of liver, fresh or frozen, was homogenised in a glass 
teflon homogeniser and subsequently transferred to a 4ml 
polypropylene tube. 0.1ml of 2M sodium acetate (pH-14). 1ml of 
phenol (water saturated), and 0.2ml of chloroformisoamyl alcohol 
mixture (49:1) were added to the homogenate with thorough mixing 
after the addition of each reagent. The final suspension was shaken 
vigorously for 10 seconds and cooled on ice for 15 minutes. Samples 
were centrifuged at 10,000g for 20 minutes at 4°C. After 
centrifugation, the aqueous phase, which contains the RNA, was 
transferred to a fresh tube, mixed with 1ml isopropanol and then 
placed at -20°C for 1 hour to precipitate RNA. The tubes were
centrifuged at 10,000g for 20 minutes at 4°C to sediment the RNA., 
and the resulting pellet was dissolved in 1.3ml of solution D, and 
precipitated with one volume of isopropanol at -20°C for 1 hour. 
After centrifugation at 10,000g for 10 minutes at 4°C the RNA pellet 
was resuspended in 75% ethanol, sedimented, vacuum dried and 
dissolved in 200ul water (sterile) at 65°C for 10 minutes and stored 
at -70°C until used.
To determine the purity of the RNA preparations, lOul aliquots 
were diluted 1:100 with sterile water and transferred to 1ml quartz 
cuvettes. The samples were scanned between 200 and 300nm and the 
absorption at 260 and 280nm was determined. A 260-280nm ratio of 
2.0 was taken as indicative of pure RNA. The RNA yield was 
calculated assuming:
Aicm/1% at 260 = 40ug/ml
2.6.2 RNA. Dot Blots with Nitrocellulose
Dot blotting was carried out routinely using an adaptation to 
the method of White and Bancroft (1982). RNA samples were diluted 
in sterile water as required to give a final RNA concentration of 1, 
2, 5 and lOul and then 150ul of 6.15M formaldehyde and 150ul of 20 x 
SSC (3M sodium chloride and 0.3M sodium citrate, pH8) were added, 
mixed and the samples were incubated at 65°C for 15 minutes.
The nitrocellulose filter was soaked in 10 x SSC and sterile 
water for 5 minutes each time. The dot blot apparatus (BRL) was 
cleaned with distilled water and acetone and assembled with the
filter according to the manufacturer's instructions. The RNA. samples 
were applied to the wells, under a slow vacuum and then washed with 
400ul 10 x SSC; the filter was removed and dried between Whatman 3MM 
paper prior to baking at 80°C for 2-3 hours. The baked filters were 
stored at room temperature between sheets of Whatman 3MM paper prior 
to hybridisation.
2.6.3 Nick Translation
The nick translation kit was obtained from BRL and the 
accompanying instructions followed:
Reagents
200ng rat cytochrome P-450 rAZ&-l DNA 
5ul dAPT, dGPT, dTTP
lOOug UAP32 dCPT
and sterile water to give a total volume of 40ul.
This was vortexed briefly and 5ul of DNA polymerase added. The 
solution was mixed and centrifuged rapidly prior to incubation for 2 
hours at 15°C. The reaction was stopped by the addition of 5ul of 
0.3M EDTA, mixed and stored on ice. A further 200ul of TNE buffer 
(lOmM Tris, lOOmM NaCl and ImM EDTA,pH8) and 5ul of salmon sperm DNA 
(2mg/ml) were added.
2.6.4 Removal of Unincorporated Alpha P32 dCTP
NACS prepac cartridges (1cm x 0.5cm) contain NACS 52, a
derivative of hydroxylapatite, were used to remove unincorporated 
alpha P32 nucleotides (Maniatis et al., 1982). Under low salt 
concentration DNA is bound to the column by the phosphates wereas 
nucleotides do not bind. In conditions of high salt concentration, 
DNA is eluted. The column was attached to a 2ml syringe and
hydrated with 5 x 1ml volumes of 2M NaCl in 10m Tris, ImM EDTA 9pH8) 
(TE) and equilibrated with 10 x 1ml washes of 0.5M NaCl in TE
buffer. The column was secured in a retort and the nick translation 
volume was loaded onto the column via the syringe barrel. The 
column was washed with 10 x 1ml volumes of 0.5M NaCl/TE buffer 
collected into Eppendorfs and eluted with 5 x 0.1ml aliquots of 2M 
NaCl in TE buffer.
2.6.5 Filter Hybridisation with Radioactive Probes
The application of nucleic acid hybridisation has been studied 
extensively (Hames and Higgins, 1985) allowing for modification to 
optimise conditions. The backed filters were soakedin 5 x SSC
before being transferred to 250ml pre-hybridisation buffer, warmed 
to 42°C in a plastic container. Pre-hybridisation was carried out at 
42°C in a shaking water bath for 7 hours. The buffer was removed 
and replaced with hybridisation buffer containing the readioactive 
probe which had previously been boiled for 5 minutes to denature the 
double stranded DNA. The filters were hydridised for a minimum of 15 
hours at 42°C in a shaking water bath.
Prehybridisatiaa Buffer
Deionised formamide 250ml
50 x Demhardet solution 50ml
(2% w/v Ficoll, 2% w/v BSA and 2% w/v
polyvinyl-pyrrolidine)
20 x SSC 125ml
Boiled salmon sperm DNA (lOmg/ml) 12.5ml
Sterile water 62.5ml
Poly A (20mg/ml stock solution) 0.25ml
Poly C (2Qmg/ml stock solution) 0.25ml
Hybridisation Buffer
Deionised formamide 250ml
50 x Denihardts solution 10ml
20 x SSC 125ml
50% Dextran sulphate 100ml
Boiled salmon sperm DNA (lQmg/ml) 5ml
Poly A (20mg/ml stock solution) 0.25ml
Poly C (20mg/ml stock solution) 0.25ml
2.6.6 Washing of Filters Following Hybridisation
The hybridisation buffer was removed and replaced with 2 x 
SSC, 0.1% (w/v) SDS for three consecutive washes at room temperature 
for 30 minutes followed by one wash in 0.5 x SSC, 0.1% (w/v) SDS for 
45 minutes at 55°C. The final wash was completed at room temperature 
in 5 x SSC for 30 minutes. The filters were dried between sheets of 
Whatman 3MM paper at 37°C for 20 minutes and then placed in an X-ray 
cassette with an intensifying screen with X-ray film (Kodak GB X2) 
for four days at -70°C. The X-ray films were developed and 
qualitative and quantitative assessment of RNA. dot blots made by the 
use of densitometry (ACD-18 Automatic Computing Densitomer, Gelman 
Inst. Co., Ann Arbor, MI, U.S.A.).
2.7 IN VIVO DETERMINATION OF DRUG METABOLISING ACTIVITY 
2.7.1* Determination of Antipyrine Metabolism
Antipyrine (AP) and its main metabolites in rat urine were 
determined according to the method of Teunissen et al., (1983) with 
some modification.
Animals were treated with the appropriate compound as 
previously described, and were housed individually in metabolic 
cages to allow for separate urine collection. Urine was collected 
24 hours prior to AP dosing (70mg/kg by gavage 24 hours after the 
last treatment with the appropriate compounds) and for a further 24 
hours from the AP dosing. Urine volume (24 hours collection) was 
measured and sodium pyrosulphite (^28205) was added to the urine to 
prevent the oxidation or breaking down of AP and metabolites to give 
a final concentration of 2g/l. The urine samples were stored at - 
20°C until used.
Analytical Procedure
To 0.5ml of urine, 0.5ml of 0.5M acetate buffer 9pH4.5), 40mg 
of ^ 28205 and lQmg of limpet acetone powder were added. The mixture 
was incubated for 2-3 hours at 37°C in a shaking water bath. After 
the incubation lOug of phenacetin (an internal standard in 50ul of 
ethanol) was added to the samples and the mixture was saturated with 
200mg NaCl and extracted with 5ml of chloroform-ethanol (9:1 v/v). 
Organic layer was collected and evaporated under reduced pressure at 
room temperature. The residue was dissolved in 0.2ral of methanol
and diluted with 0.5ml of lQmM acetate buffer containing 12.5mg of 
Na2S20ij (freshly prepared). Of this solution, 15ul was injected 
into the HPLC system.
Calibration Graphs and Standard Curves
Calibration graphs were prepared by spiking blank samples with 
AP or the metabolites to be measured ranging from 1.5-10ug/ml (from 
stock solutions of lmg/ml) and were subsequently treated as the 
urine samples.
2.7.2 Metabolite Separation and Chromatographic Conditions
The liquid chromatographic system (Kipp Analytics, Holland) 
consists of a 9208 pumping device and a 9203 spectrophotometer 
detector set at 245nm connected to a chart recorder. The separation 
of the AP and its metabolites was carried out by the use of a column 
(I.D., 4mm x 11cm) packed with Hypersil 3 )DS, 5um (Technical 
Assoc., Canaga Park, CA, U.S.A.). The eluent for the separation 
consisted of a mixture of 20mM phosphate buffer (pH7.2) and 
acetonitrile (100:10) containing Na2S205(2g/l). The flow rate was 
set at 1.5ml/min.
Metabolite quantitation was calculated from the peak height of 
the internal standard, the drug and metabolites as well as reference 
to a standard curve.
2.7.3 Pentobarbital Sleeping Time
Wistar-albino rats weighing 80-100g (10 rats per group) were 
dosed with the appropriate compounds, as described previously. 
Pentobarbital (3Qmg/kg in volumes of 0.09-0.13ml) was given 
intraperitoneally to the rats 24 hours after the last dose of the 
herbicides. Sleeping time was measured by means of the rats gaining 
the right of reflex after they were put on their backs.
2.7.4 Zoxazolamine Paralysis Time
Rats of Wistar-albino strain (100-120) (10 rats per group, 15 
rats for control)were dosed with the appropriate compound for three 
days as previously described. Zoxazolamine was given at 70mg/kg 
dose intraperitoneally and the zoxazolamine paralysis time was 
recorded.
2.8 STATISTICAL ANALYSIS
Statistical evaluation was carried out by the Student's t- 
test. Multi-dimensional regression analysis was performed using r 
(multiple correlation coefficient) and s (standard error of the 
estimate) to test the quality of the regression equations.
CHAPTER THREE
EFFECT OF CHLOROPHENOXYACID HERBICIDES ON MICROSOMAL 
CYTOCHROME P-450 TVA1 IN RAT LIVER AND KIDNEY
CHAPTER 3
EFFECT OF CHI/)ROPHENOXYACID HERBICIDES ON MICROSOMAL 
CYTOCHROME P-450 IVA1 IN RAT LIVER AND KIDNEY
3.1. INTRODUCTION
In rodents, the administration of several hypolipidaemic 
agents is associated with hepatomegaly and with marked proliferation 
of both peroxisomes and the endoplasmic reticulum (Hess et al., 
1965; Reddy and Lalwani, 1983; Hawkins et al., 1987). The early 
hepatic changes observed in rats on administration of hypolipidaemic 
agents such as clofibrate include hepatomegaly, proliferation of 
peroxisomes and more recently, the induction of a microsomal 
isoenzyme of cytochrome P-450 (termed cytochrome P-450 IVA1), the 
latter specifically catalysing the hydroxylation of fatty acids 
(Tamburini et al., 1984). The relationship between the induction of 
microsomal and peroxisomal enzymes following hypolipidaemic 
challenge is thought to be closely linked (Lake et al., 1986; Sharma 
et al., 1988a and b).
Structurally related to the oxyisobutyrate class of 
hypolipidaemics, the phenoxy acid herbicides have been shown to 
induce hepatic ^ -oxidation and peroxisomal proliferation in rodents 
(Vainio et al., 1983; Kawashima et al., 1984a; Hietanin et al., 
1985). In addition, these herbicides induce several other enzyme 
activities in rodent liver including catalase (Vainio et al., 1983), 
glutathione reductase and glutathione peroxidase (Hietanin et al.,
68
1985), glutathione S-transferase (Vessey and Boyer, 1984) and 
epoxide hydrolase (Lundgrun et al., 1987a) in rat and mouse liver.
In view of the above, the present study was undertaken to 
investigate the effect of seven phenoxy herbicides on the cytochrome 
P-450 mixed-function oxidase system in rat liver and kidney 
microsomes, and in particular, the previously described, 
hypolipidaemic-induced cytochrome P-450 IVA1 isoenzyme.
3.2 RESULTS
3.2.1 Liver Microsomes
As can be seen from Fig. 3.1 intragastric exposure to some 
phenoxy acid herbicides had a significant effect on rat liver/body 
weight ratio. Body weight gain was normal, in rats treated with
2,4-DB, CPA and MCPA compared to control groups, whereas treatment 
of rats with 2,4-DP and 2,4,5-Tp resulted in loss of about 6-7% of 
body weight at the highest dose treatment. At the lower doses there 
was no clear influence of drug treatment on body weight gain when 
compared to control. The liver/body weight ratio, as an indication 
of change in liver size, was normal in rats treated with 2,4-DB, 
MCPA and CPA over the three dose levels (Fig.3.1), whereas 2,4-DP 
(25%), 2,4,5-T (25%) and 2,4,5-Tp (50%) increased the liver/body 
weight ratio significantly. The increase in liver/body weight ratio
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did not correlate well, in general, with the increase in total 
cytochrome P-450 content (Figs. 3.1 and 3.2).
Only 2,4-D treatment at 200mg/kg showed a decrease (11%) in 
liver /body weight ratio as compared to control (Fig. 3.1). The 
decrease in body weight and liver/body weight ratio after treatment 
with 2,4-D(200mg/kg) may be explained by the effect of the compound 
on the ability of the rats to move and feed. At the above 
doselevel, 2,4-D treatment increased the total cytochrome P-450 
content by 100% over the control levels (p < 0.05) (Fig. 3.2).
Total cytochrome P-450 content was increased significantly by 
all seven compounds in a dose-dependent manner (Fig. 3.2). The 
increase of total cytochrome P-450 content in liver microsomes at 
the highest dose level ranging from 148% (p > 0.05) in the case of 
CPA (300mg/kg) to 228% (p > 0.01) after treatment with 2,4,5-T 
(200mg/kg). The correlation between liver/body weight ratio and 
cytochrome P-450 content showed significance in the case of 2,4-DP,
2,4,5-T, 2,4,5-TP (Fig. 3.1 and 3.2): it should be noted that as in 
liver/body weight ratio, 2,4,5-T and 2,4,5-TP produced the highest 
increase in total cytochrome P-450 content (128%, 89% respectively) 
over the control level and the better correlation over the three 
dose levels.
Among the seven compounds tested, the greatest induction of 
ethoxyresorufin-O-deethylase activity (a marker substrate for 
cytochrome P-450 IA1) was obtained after MCPA treatment (Fig. 3.3).
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MCPA treatment (200mg/kg and 300mg/kg) increased ethoxyresorufin-O- 
deethylase activity significantly (2.2 - 2.4-fold) with statistical 
significance of p < 0.01. 2,4-D and 2,4,5-T at a dose of 200mg/kg
also produced significant (1.8 and 1.6-fold respectively with p < 
0.05) increase of the lenzyme activity over the control levels (Fig. 
3.3). Other compounds produced no significant changes in the enzyme 
activity over the different dose levels given. By contrast, none of 
the compounds tested had any significant influence on benzphetamine- 
N-demethylase activity (a marker substrate for cytochrome P-450 
IIB1) (Fig. 3.4).
The structural similarity of these phenoxy acids to clofibrate 
suggested that they may have an influence on fatty acid metabolism. 
Since lauric acid was shown to be a suitable substrate for 
clofibrate-induced cytochrome P-450 IVA1 (Tamburini et al., 1984).
I then investigated the ability of the above seven phenoxy acid 
compounds to induce lauric acid hydroxylase activity (namely, 
cytochrome P-450 IVA1 which is responsible for the 12-hydroxylation 
of laurice acid).
Upon the administration of the phenoxy acids to the rats, the 
liver microsomal laurate 12-hydroxylase activity was elevated by all 
seven compounds significantly at the highest dose level (Fig. 3.5). 
At the lowest dose of 5Qmg/kg, 2,4,5-TP produced the greatest 
induction (8.2-fold), reaching an apparent saturation level, whereas
2,4-DP showed about a 5-fold increase in the 12-hydroxylation of 
laurice acid. With the exception of the above two compounds, 2,4-D,
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2,4-DB and 2,4,5-T showed a steady increase in the laurate 12-
hydroxylation over the three dose levels (Fig. 3.5). The other two 
compounds, MCPA and CPA, given at dose levels of 100, 200 and 
300mg/kg, as indicated in Methods, produced the highest induction 
(8.3-fold in the case of MCPA at 30Qmg/kg) and the lowest (3-fold) 
as in the case of CPA (Fig.3.5). At the highest dose levels, the 
12-hydroxylation of lauric acid induction was statistically 
significant at p < 0.01 (2,4-D and CPA) and p < 0.001 (2,4-DP,
2,4,5-T, 2,4,5-TP and MCPA) as compared to the control value.
The 11-hydroxylation of lauric acid was also induced by 
several of the phenoxy acid tested (Fig. 3.6). Although the
induction of this activity was substantially less marked than for
the corresponding 12-hydroxylase activity, it was significantly 
induced by 2,4-DP (167%) (p < 0.05), 2,4,5-TP (264%) (p < 0.001), 
MCPA (237%) (p < 0.01) and CPA (251%) (p < 0.01) and statistically 
significant when compared to control. 2,4-D, 2,4-DB and 2,4,5-T 
showed no significant induction of 11-hydroxylation of lauric acid 
over the dose levels administered. From Figs. 3.5 and 3.6 it is 
clear that, with the exception of CPA, most inducers of 12- 
hydroxylase activity are also inducers of 11-hydroxylase activity 
with good correlation (Table 3.2 and 3.3).
In view of the fact that all seven compounds induced the
microsomal 11- and 12-lauric acid hydroxylase activity (Figs. 3.5 
and 3.6), the influence of these compounds on the amount of 
immunochemically-determined cytochrome P-450 IVA1 was investigated.
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As shown in Fig. 3.7, with the exception of CPA, all phenoxy acids 
substantially induced (3-5 -fold) the level of this isoenzyme in rat 
liver microsomes. It is clear from the graph that, with the 
exception of 2,4,5-TP, the induction of cytochrome P-450 IVA1 was 
dose-dependent with a good linearity over the three dose levels. It 
is also clear that 2,4,5-TP produced the greatest increase of this 
isoenzyme as in the case of 12-hydroxylation of lauric acid (Fig. 
3.5) at 200mg/kg dose level. As in Table 3.2 and 3.3 it is not 
surprising to see a good correlation between laurice acid 12- 
hydroxylation and the specific content of cytochrome P-450 IVA1 and 
also to note the statistically significant induction (p < 0.01 or p 
< 0.001) of this isoenzyme at the highest dose levels given (Table 
3.1).
Using antibody raised against clofibrate-induced cytochrome P- 
450 IVA1, I blotted the control and test microsomal preparations 
against this antibody (Fig. 3.8). As can be seen from Fig. 3.8, a 
low constitutive level of the isoenzyme was identified in control 
liver, the magnitude of which was substantially increased in phenoxy 
acid-pretreated liver microsomal fractions at the top dose levels 
given. It is clear that the antibody used only reacts with a major 
protein band of a molecular weight corresponding to authentic 
cytochrome P-450 IVA1, thus lending further credence to the ELISA- 
derived values for cytochrome P-450 IVA1 given in Table 3.1 and Fig. 
3.7. Taking this into account, I could not see any real increase in 
protein in the range of 51,500 molecular weight on SDS-PAGE 9Fig. 
3.9).
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Figure 3.9 SDS-PAGE of liver microsomes from 
phenoxy acid pretreated rats.
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Samples were loaded as follows: tracks (1) and (10) standard 
molecular weight markers as described in Materials and Methods, 
track (2) control, (.3) 2,4-D, (4) 2,4-DP, (5) 2,4-DB,. (6) 2,4,5-T, 
(7) 2,4,5-TP, (8) MCPA and track (9) CPA loaded at 15 mg of 
microsomal protein. Test doses were as described in the legend 
to Figure 3.8.
Western blot analysis using antibody raised against 3- 
methylcholanthrene-induced cytochrome P-450 IA1 (Fig. 3.10) showed 
no difference between microsomes from control and treated animals 
which may indicate that the increase in ethoxyresorufin-deethylase 
activity (Fig. 3.3) with some of the phenoxy acids is only the 
result of direct activation of the enzyme protein and not the result 
of any increase in the amount of enzyme protein.
3.2.2 Kidney Microsomes
Different effects on the renal cytochrome P-450 system were 
observed after the treatment of rats with the individual phenoxy 
acid compounds (Table 3.4) at the highest dose level.
Kidney microsomal total cytochrome P-450 content was not 
induced by any of the compounds tested (Fig. 3.11) whereas 2,4-DB,
2,4,5-TP and MCPA treatment showed about 100% increase in 
ethoxyresorufin-O-deethylase activity over the control level (Fig. 
3.12). The picture is similar to that of the ethoxyresorufin-O- 
deethylase activity in liver microsomes (Fig. 3.3) in showing that 
MCPA being the highest inducer (120% over control level). Similar 
compound-dependent effects can be seen with benzphetamine-N- 
demethylase activity in a manner comparable to that of liver 
microsomes (Fig. 3.13). Again MCPA showed 80% induction over the 
control whereas 2,4,5-T showed the highest induction with 100% over
83
Figure 3.10 Wes'tern blot analysis of microsomes from
phenoxy acid, pretreated rats for cytochrome
P-450IA1
I*!"**-
'--?1 2 3 4 5 6 7 8 9
Wesrern blot analysis was carried out as described 
in methods,. Track (1) contains 0.05 pmol of pure
3-MC inducible cytochrome P-450 , tracks (2) control 
, (3) CPA , (4)'!MCPA ,' ’ (5) 2..4-D'1 , (6) 2,4-DP , (7)
2,4-DB , (8) 2,4,5-T and (9) 2,4,5-TP loaded at 5
pmol of total cytochrome P-450.
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control. Decrease in this enzyme activity was seen with 2,4,5-TP 
(65% of control) and to a lesser extent 2,4-DB.
Renal lauric acid 11- and 12-hydroxylation was also minimally 
affected by the phenoxy acetic acids. In contrast to the liver it 
is surprising to see a decrease in the laurate 12-hydroxylase 
activity with some of the compounds (CPA = 60% and 2,4,5-T = 68% of 
control) (Fig.3.14). None of the compounds increased the 11-or 12- 
hydroxylation of lauric acid (Fig. 3.14 and 3.15). There was a 
decrease in the 11-hydroxylation of lauric acid by some of the 
compounds, specifically 2,4-D, 2,4,5-T and CPA (53%, 73% and 67% of 
control respectively) (Fig. 3.15). This was made clearer by the 
ELISA analysis for the specific cytochrome P-450 IVA1 (Fig.3.16). 
It is clear that no significant change can be seen in the level of 
this isoenzyme in kidney microsomes. From these results with kidney 
microsomes, it was concluded that, unlike liver microsomes, the 
chlorophenoxy acids studied have no profound effect on the 
cytochrome P-450 mixed-function oxidase in the kidney microsomes 
(Table 3.4).
3.3. DISCUSSION
Although chlorophenoxy acid compounds have been documented to 
induce several hepatic enzyme activities (Vainio et al., 1983;
Kawashima et al., 1984a; Vessey and Boyer, 1984; Hietanin et al., 
1985; Lundgren et al. ,1987a & b), their ability to influence the 
cytochrome P-450 dependent mixed function oxidase system is not so
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well defined. In this study my results have shown that 
structurally-related chlorophenoxy acids are relatively specific 
inducers of the previously described, hypolipidaemic-induced 
cytochrome P-450 IVA1 isoenzyme (Gibson et al.. 1982; Tamburini et 
al., 1984; Bains et al., 1985). Looking at Table 3.1 it is clear 
that all seven compounds significantly increased the specific 
cytochrome P-450 IVA1 isoenzyme at the top dose levels. This 
induction of specific cytochrome P-450 IVA1 isoenzyme is coupled 
with a significant increase in laurate 12-hydroxylase activity 
(Figs. 3.5 and 3.7). For CPA, the significant increase in laurate 
12-hydroxylase activity was not coupled with significant cytochrome 
P-450 IVA1 induction. Thus, by using these chlorinated acids as an 
experimental tool, I have shown the close correlation that exists 
between lauric acid 12-hydroxylase activity and the amount of the 
cytochrome P-450 IVA1 (Tables 3.2 and 3.3).
Although I have not attempted to define precisely a structure- 
activity relationship for the chlorophenoxy acids, it is apparent 
that a greater degree of chlorination in the aromatic ring results 
in a greater induction of laurate 12-hydroxylase activity (compare
2,4,5-T > 2,4-D > CPA and 2,4,5-TP > 2,4-DP) (Fig. 3.5) when 
considered on a mg/kg dose basis. These extensively chlorinated, 
potent inducers are even more potent still, when compared on a 
moles/kg basis (data not shown). Whether this apparent relative 
potency is a function of lipophilicity or pKa and therefore the 
’true bio-availability’ of the inducer or a preferred steric 
requirement of the inducer, is not clear from my studies, and
EF
FE
CT
S 
OF
 
PH
EN
OX
YA
CI
D 
HE
RB
IC
ID
ES
 
ON 
RA
T 
LI
VE
R 
WE
IG
HT
 
AN
D 
MI
CR
OS
OM
AL
 
CY
TO
CH
RO
ME
 
P-
45
0
>1rtf
•
rtf r—1 1—I
O <(1) O >O H
0 o O
o V o  in
• PM ID ^ * He He He He
0  Q ^  I ^ He He He He He He
0  • •*» 1 PM H He He He He He He
■H W r l PM 0 -N
■P o i—1 -p CM in CO CO VO m
0+1 • o o o 00 • • • • • • CO
^  C O ■H g + ) • O CM in O l—1 •P rtf V +H 0 VO OH CM •—I CM CO CM
-P 0 Pi •H \ 4H — '— '—' ■—■ — '—1 — '—
0 g * O H  O LT) CM O CM r - CO co r->•H He 0  O o CO CO CM CO in CM OCO Pj g o\o • • • • • • • •
U -p - w  0  — o O O O O O O O•H 0  ir>
M (UO
-P CO •
co a) o o
0  p \ / in
tn CMPM He
0  * l He He He
>i p PM He He He He He He
,Q •• 00 CM i—1 He CO He CTi0 CO 0 I—I CM O i—1 CO CM CO O
T5 0  rH g — • • • • • • • •
CL) >—• O O tn o o O o O O o O
P rtf P p g
0 >  -P ,0 \ +  1 +  1 +  1 +1 +  1 +  1 +  1 +  1
-p 0 H U H
W ,0 0 0  O 0 o o CM CO i—1 r - 00
-H U O -P -P g 00 VO CO 00 m CM rH
0  rtf O >i 0 • • • • • • • •
•rl H  ,Ej EH O — o 1—1 i—1 i—i 1—1 i—i 1-1 i—1
g P1
rtf • £
tn
fl)X  C
P \  0 He
0 tn CO He * He
£  g -H >i H< * He
p Ti CO O CM CM CO m in 00
^  O 0 O • « • • • ■ • •
w o  a A  — O 1—1 O O O O O o
r -  CM g \  o\°
• o P — +1 +  1 +  1 +  1 +  1 +  1 +  1 +  i
tnm  u 0
•p o > • in <r» cn o 00 CM 00 o
0 •H 4) • • • • • • • •i—1 *H PI £ in VO VO VO 00 in VO
0 0
•H > 0
0  O
0  H  f!
0  0 to
£ 0  O m iH
•H W -H 0  0
m o *p g
0  0  -H • -H
T5 0 O 0 in cn in CO <T\ CO VO VO
0  tn S  0 i—i
•H
W -P 0)
T! 0
0  1—13 in 0
O >i o -P
OU 0  *H 0 PM
g v  -p 0 i—i EH Eh
o w g o di PQ 1 1U co -H -P p Q Q Q in in
•P 0 -p 1 1 l *. <0 P 0 0 0 <.0 0 -P P 0 K y PM
^ > H W EH U CM CM CM CM CM s U
93
remains a topic for further exploration.
The inter-relationship between the cytochrome P-450 dependent 
parameters induced by this class of compounds is clearly seen in the 
correlation matrices of Tables 3.2 and 3.3. For example, the 
correlation between 12-hydroxylase activity and specific cytochrome 
P-450 IVA1 induced by 2,4,5-TP is high (0.968), whereas the 
correlation between both benzphetamine N-demethylase and 
ethoxyresorufin-O-deethylase and cytochrome P-450 IVA1 is very low 
(0.181 and 0.315 respectively). Similarly, the lack of correlation 
between 12-hydroxylase and both ethoxyresorufin-O-deethylase and 
benzphetamine N-demethylase (0.086 and 0.058 respectively) indicates 
that these three substrates are preferentially metabolised by 
different isoenzymes of cytochrome P-450. This latter conclusion is 
consistent with previously published data on the substrate 
specificity of purified cytochrome P-450 IVA1, P-450 IIB1 and P-450 
IA1 in reconstituted enzyme systems (Tamburini et al., 1984). It is 
worth noting that an excellent correlation (0. 975) was observed
between cytochrome P-450 IVA1 content and lauric acid 11-hydroxylase 
activity after 2,4,5-TP treatment (Table 3.3). This observation may 
be rationalised by the fact that highly purified, 
electrophoretically homogeneous cytochrome P-450 IVA1 retains 
residual 11-hydroxylase activity (Gibson et al., 1982; Tamburini et 
al., 1984) and would thus feature strongly in the correlation 
matrix. However, it must be emphasised that cytochrome P-450 IVA1 
preferentially hydroxylates lauric acid in the 12-position, as 
reflected in the 12:11 product ratio of approximately 10.1 (Gibson 
et al., 1982; Tamburini, 1984). It should be noted that all other
s
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compounds used produced a significant correlation (higher than 
0.666) between laurate 12-hydroxylase and cytochrome P-450 IVA1 
(Table 3.2) with the exception of 2,4-DB and CPA, all other 
compounds produced good correlation between total cytochrome P-450 
content and laurate 12-hydroxylase and also between total cytochrome 
content and specific cytochrome P-450 IVA1 as shown in Table 3.2.
My data indicates that some of the chlorinated phenoxy acids
(particularly MCPA, 2,4-D and 2,4,5-T) may function as ,mixed
inducers1 of cytochrome P-450, in that ethoxyresorufin-O-deethylase
activity (cytochrome P-450 IAl-dependent) is additionally induced.
However, this is not true for all the compounds studied (Fig. 3.3).
For the above active inducers, the extent of ethoxyresorufin-O-
deethylase induction is clearly less (approximately 2-fold) than the
12-hydroxylase induction (approximately 8-fold) after 2,4,5-TP
treatment. It is only 2,4,-D and MCPA that produced good
correlation between total cytochrome P-450 content and
ethoxyresorufin-O-deethylase (Table 3.2). By contrast to the above,
cytochrome P-450 IIBl-dependent benzphetamine N-demethylase activity
is not induced by any of the seven compounds tested even at the
highest dose administered. Taken collectively, this information
*
indicates that the cytochrome P-450 IVA1, P-450 IIB1 isoenzymes are 
differentially regulated by their corresponding inducers, a 
conclusion that is consistent with the available literature 
(Hardwick et al., 1987; Nebert et al., 1987).
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For kidney microsomes, no statistical analysis could be 
completed on the data due to an insufficient number of kidney 
samples (one microsomal pool per dose level). From Table 3.4 there 
was no clear pattern of increase or decrease in the enzyme activity 
tested. It is only with benzphe tamine-N-deme thylase and 
ethoxyresorufin-O-deethylase activity that some of the parameter was 
increased to a maximum of 2-fold. The only significant result that 
can be noted is that the kidney microsomal content of cytochrome P- 
450 IVA1 (22.5% of total P-450) is much higher than that of liver 
microsomes (6.8% of P-450) at the control level. From this I 
conclude that the chlorophenoxy acids studied, after their 
metabolism in the liver (or the parent compound) have no apparent 
effect on the kidney parameters tested, which may be explained, in 
part, by the lack of either uptake or renal cellular bio­
availability of the inducer.
In conclusion, I have shown that chlorophenoxy acids are 
relatively specific inducers of the cytochrome P-450 IVAl-dependent, 
lauric acid 12-hydroxylase enzyme. In view of the structural 
similarity of these chlorinated phenoxy acids to clofibrate and 
their ability to produce peroxisomal proliferation in rodent liver 
(Vainio et al., 1983; Kawashima et al., 1984; Heitanin et al.,
1985), they may share a common mode of induction with the 
oxyisobutyrate class of peroxisome proliferators. This also 
suggests that my results and previous results using these phenoxy 
acid class of compounds can fit into the scheme proposal by Sharma 
et al., 1988a, in which an hypothesis is presented whereby an early
biological response in the hypolipidaemic induction of microsomal 
cytochrome P-450 IVA1 resulting in w-hydroxy fatty acids and their 
subsequent further oxidation to dicarboxylic acids, the latter 
providing the peroxisomal stimulus for peroxisomal proliferation.
CHAPTER FOUR
EFFECT OF PRETREATMENT WITH CHLOROPHENOLS ON RAT HEPATIC AND 
KIDNEY CYTOCHROME P-450 MIXED FUNCTION OXIDASE ACTIVITIES
CHAPTER 4
EFFECT OF PRETREATMENT WITH CHLOROPHENOLS ON RAT 
HEPATIC AND KIDNEY CYTOCHROME P-450 MIXED FUNCTION 
OXIDASE ACTIVITIES
4.1 INTRODUCTION
In view of the fact that chlorinated phenoxy acids 
preferentially induced fatty acid hydroxylation and cytochrome P-450 
IVAI in rat liver microsomes (Chapter 3). It was decided to 
investigate the possibility of post-metabolism involvement of 
derivatives of these phenoxy acids in the induction process, namely 
the corresponding phenols, and four phenols, 4-chlorophenol (CP),
2,4-dichlorophenol (DCP), 2,4,5-trichlorophenol (TCP) and 4-chloro-2- 
methylphenol (MOP) Fig.4.1 were chosen for study. These were used in 
this study to determine their possible inductive effect on the 
cytochrome P-450 system in rat liver and kidney microsomes, as they 
may possibly be formed from the corresponding chlorophenoxy acids. 
Although alkyl carboxylic acids may also be theoretically produced 
from the parent compounds, these carboxylic acids were not 
investigated further.
Although phenolic compounds are well known to be excreted in 
urine by man and many other species (Williams 1969), the effect of 
phenols, and in particular chlorinated phenols on the cytochrome P- 
450 system is not very well documented. The metabolism of phenols 
has been studied quantitatively and qualitatively by Capel et al 
(1972 a,b) and Deichmann and Keplinger (1981). The metabolism of 
phenolic compounds and their excretion as phenyl glucuronic acid and
Figure 4,1 Chemical structure of phenols studied
OHCl
Cl
Cl OH
4-Chlorophenol (CP)
2,4-Dichlorophenol (DCP)
Cl
OHCl
Cl CH
2,4,5-Trichlorophenol (TCP)
OH 4-Chloro-2-methylphenol (MCP)
phenyl sulphate metabolites have been described by Kao et al 
(1979),with phenol sulphotransferase being the enzyme catalysing the 
sulphate conjugation of phenols (Weinshilboum, 1986).
Chlorophenols (the subject of this study) are used primarily as 
pesticides and as intermediates in the production of pesticides 
(Freiter. 1979). 4-chlorophenol and 2,4-dichlorophenol are used 
principally as an intermediate in the production of herbicides such 
as CPA, 2,4-D, 2,4-DP, 2,4-DB and related compounds, whereas 4- 
chloro-2-methylphenol is used in the manufacture of MCPA.
The major use of 2,4,5-trichlorophenol (TCP) has been as an 
intermediate in the manufacture of industrial and agricultural 
chemicals, including 2,4,5-T and 2,4,5-TP. 2,4,5-trichlorophenol and 
its salts have been used as preservatives in the textile industry, in 
the adhesives industry for polyvinyl acetate emulsions, in the 
leather industry and in the automotive industry for preservation of 
rubber gaskets. The water soluble sodium salts have been used to 
preserve casein-derived adhesives, to preserve and stabilize metal 
cutting fluids and as an antimicrobial agent in cooling tower water 
and in pulp and paper mills (Freiter 1979).
To establish whether the induction of cytochrome P-450 system as 
described in chapter 3 is the result of the phenoxyacids themselves 
or a result of a possible phenol formation, I investigated the effect 
of four phenol compounds (corresponding to the phenoxyacids) on the
cytochrome P-450 system in liver and kidney microsomes of Wistar 
Albino rats.
4.2 RESULTS
4.2.1. Liver Microsomes
As described in methods, the phenols:( 4-chlorophenol, 2,4- 
dichlorophenol, 2,4,5-trichlorophenol and 4-chloro-2-methylphenol 
(Fig.4.1),) were given to rats at doses of 50, 100 and 200 mg/kg/day 
for three days. None of the phenols produced any effect on body 
weight gain and on liver/body weight ratio (Fig. 4.2) as compared to 
control. Signs of liver enlargement were therefore not observed, an 
indication of the absence of hepatomegaly produced by some of the 
chlorinated phenoxyacids previously studied (Chapter 3).
Total content of cytochrome P-450 in liver microsomes was not 
induced by any of the phenols studied. In contrast, there was a 
slight but significant decrease after DCP and TCP treatment (90% of 
control) at 200 mg/kg/day for three days (Fig.4.3). At the lower 
dose of 50 mg/kg, CP, TCP and MCP, treatment produced a 10-15% 
decrease in total cytochrome P-450 content. None of the phenol 
treatments showed a consistency in decreasing the total cytochrome P- 
450 content.
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The activity of cytochrome P-450 IIBI was measured by means of 
using benzphetamine as the substrate. Benzphetamine-N-demethylase 
was significantly reduced by some of the phenols treatment (Fig.4.4). 
The most effective phenol in reducing the enzyme activity was CP in a 
dose-dependent manner. At the highest dose level (200 mg/kg), CP, 
DCP and TCP (P<0.01 and P<0.001) reduced significantly the enzyme 
activity (32%, 25% and 77% of control respectively). Although 
MCPsignificantly reduced benzphetamine-N-demethylase activity at 50 
mg/kg and 100 mg/kg (80% and 76% of control respectively), 200 mg/kg 
treatment resulted in no effect on the enzyme activity. For 
ethoxyoresorufin-O-deethylase activity, as a marker for cytochrome P- 
450 IA1 and P-450 IA2, the effect is quite the opposite (Fig.4.5). 
All of the four phenol compounds significantly induced this enzyme 
activity. The most potent inducer was MCP over the three dose 
levels. At 200 mg/kg dose level MCP induced the ethoxyresorufin-O- 
deethylase activity significantly (262% over the control, P<0.001) 
whereas CP was the least active inducer (145% over the control, 
P<0.001). Overall, the induction of this latter enzyme over the 
three dose levels gave a good correlation in regard to induction/dose 
relationship (Fig.4.5).
Unlike their chlorephenoxy acid analogues the immunochemically 
determined specific cytochrome P-450 IVAI concentrations as 
determined by ELISA showed no significant change from that of control 
after the phenol pre-treatment (Fig.4.6). This conclusion was 
supported by Western blot analyses of the microsomal fractions 
derived from the livers of phenol-pre-treated animals. As shown in
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Figure 4.7 Western blot analysis of microsomes for 
cytochrome P-450IVA1 after phenol, 
pretreatment.
• -;i     . 2. ..... 3  • • • - A.-'- . 5  - •• • 6 -
Western blot analysis and dosing was carried out as described 
in methods. The samples were loaded as follows: track (1)
2 pmol of electrophoretically pure rat P-450IVA1, (2) control, 
C3) CP, (4) DCP, (5) TCP and (6) MCP, loaded at 5 pmol of 
total cytochrome P-450. Control animals received peanut oil.
Fig.4.7,when the microsomal preparations were blotted against the 
cytochrome P-450 IVAI antibody, the magnitude of the isoenzyme level 
identifiable in the control was quite similar to that of phenol-pre­
treated liver microsomal fractions. By contrast, the associated 
cytochrome P-450 IVAI-driven lauric acid hydroxylase is slightly 
induced by some of the compounds. Laurate 12-hydroxylase activity 
was only marginally induced by pretreatment with CP and MCP 
(Fig.4.8). There was an irregular increase and decrease in the 
enzyme activity over the different dose levels after the pre­
treatment with CP, DCP and TCP. Similarly laurate 11-hydroxylase 
activity was induced by some of the compounds (Fig.4.9). MCP was 
shown to be the highest inducer (165% of control, P<0.01),whereas DCP 
showed a slight but not significant decrease (88% of control) of 
enzyme activity. None of the enzyme activities could be correlated 
with each other.
4.2.2 Kidney microsomes
The effect of phenols administration on total cytochrome P-450 
content is shown in Fig.4.10. A small decrease (80% of control) 
inthe total content of the enzyme was seen after MCP treatment and 
less (85%) with TCP treatment. CP and DCP showed no apparent change 
in the total cytochrome P-450 content. The catalytic activities of 
phenol-treated kidney microsomes showed differing effects on the 
dealkylation of both benzphetamine and ethoxyresorufin, good markers 
for the cytochrome P-450 IIBI and P-450 IAI isoenzymes respectively. 
Benzphetamine-N-demethylase activity in kidney microsomes was
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slightly reduced (78% of control) by TCP and MCP at the highest dose 
level (200 mg/kg) (Fig.4.11), whereas only CP showed some increase in 
the enzyme activity (149% of control at a dose of 200 mg/kg). With 
respect to ethoxyresorufin-O-deethylase activity only MCP produced a 
noticeable increase in the enzyme activity (204% of control) 
(Fig.4.12). TCP reduced this latter enzyme activity to 67% of 
control, whereas CP and DCP showed a slight increase at the top dose 
level.
Specific cytochrome P-450 IVA1 isoenzyme levels in kidney 
microsomes from control animals were shown to be 25% of the total 
cytochrome P-450 population (Fig.4.13) and none of the phenols 
studied showed any real effect on these isoenzyme levels. In 
addition to the above, with the exception of MCP, none of the phenols 
studied had any noticeable effect on the laurate 12-hydroxylase 
activity (Fig.4.14,15). MCP showed a slight decrease in the laurate- 
12-hydroxylase activity (80% of control). This is also the case with 
laurate 11-hydroxylase activity (Fig.4.16) where only DCP showed some 
increase (190% of control) in the enzyme activity whereas TCD and 
MCP reduced the enzyme activity (75% of control) at the top dose 
level of 200 mg/kg.
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Figure 4.14 Western blot analysis of kidney microsomes 
from rats pretreated with phenolw
i 2 v 3 4 5 v  6 ..J
Western blot analysis was performed as described in 
methods .Tracks represents(1) standard (2 pmol pure 
cytochrome P-450IVA1) , (2) control j (3) CP j (4)
DCP ; (5) TCP ; and (6) MCP loaded at 5 pmol of total 
cytochrome P-450.
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4.3.DISCUSSION
The data presented in this chapter demonstrate the lack of real 
effect of chlorinated pre-treatment on the cytochrame--P-450 mixed- 
function oxidase system in rat liver and kidney microsomes. In the 
previous study (Chapter 3) I showed that some of the chlorinated 
phenoxyacids preferentially induced the cytochrome P-450 IVAI 
isoenzyme in the rat liver microsomes in a magnitude which could not 
be achieved by pre-treating the rats with the corresponding 
chlorinated phenols. This may suggest that either chlorophenoxyacids 
directly induce the activity of cytochrome P-450 IVAI in liver 
microsomes or that a different phenol metabolite is involved.
As can be seen in table 4.1 and 4.2, total cytochrome P-450 
content, cytochrome P-450 IIB1 and cytochrome P-450 IA1 was not 
induced significantly in rat liver and kidney microsomes as a result 
of chlorophenol pre-treatment. An important finding is the lack of 
induction of cytochrome P-450 IVAI in the rat liver microsomes (Fig. 
4.6-9) which suggests that chlorinated phenols are not involved in 
the induction of this particular isoenzyme (Chapter 3). This may be 
expected since earlier reports on the metabolism of chlorinated 
phenoxyacids in animals and man suggest that a very high percentage 
of the compounds are excreted in the urine unchanged (Piper et al 
1973, Gehring et al 1973, Elo 1976).
Sharma et al (1988a) presented a scheme whereby a relationship 
between the induction of cytochrome P-450 IVAI and peroxisomal /B- 
oxidation has been proposed. In this scheme the induction of
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cytochrome P-450 IVAI by hypolipidaemic drugs is proceeding, followed 
by an increase in the medium and long chain fatty acids and this 
provides a substrate for the increase in peroxisomal and 
mitochondrial ^-oxidation. The chlorinated phenoxyacids studied in 
the previous chapter can be fitted in this scheme since they 
significantly induced cytochrome P-450 IVAI and were previously shown 
to induce peroxisomal J3 -oxidation (Vaino et al 1983, Kawashima et al 
1984a and b, Hietanen et al 1985). In regard to chlorinated phenols, 
there is no significant induction of this isoenzyme, with the lack of 
reports of peroxisomal JB-oxidation induction which rule out the 
possibility of fitting into this scheme.
It is surprising to see a real decrease in liver microsomal 
benzphe t amine-N-deme thylase activity after CP treatment. This 
isoenzyme activity was reduced in a dose-dependent manner reaching 
32% of control at the highest dose level (Fig.4.4). None of the 
other compounds had any significant effect on this isoenzyme in liver 
or kidney microsomes. It is not clear why such a drop in the 
catalytic activity of cytochrome P-450 IIB1 occurs after CP 
treatment. Cytochrome P-450 IA1 was significantly induced at the 
highest dose levels by MCP and DCP and to a lesser extent by TCP and 
CP. This picture is similar to that seen with chlorophenoxyacids 
treatment. It is possible that chlorophenol and chlorophenoxyacid 
induction of cytochrome P-450 IA1 is the result of further metabolism 
of these compounds to monomeric and dimeric compounds, including 
catechol and quinone metabolites similar to that seen with TCP 
metabolism by rat liver S-9 fractions (Butte et al 1988).'
In conclusion, the pre-treatment of rats with chlorophenols 
showed no real effect on liver and kidney microsomal cytochrome P-450 
IIB1 and P-450 IVAI. The small induction of cytochrome P-450 IA1 
seen after chlorophenol and phenoxy acid treatment is not compatible 
with the large induction seen with typical inducers of this isoenzyme 
such as 3-methylcholanthrene and this may be attributed to a common 
contaminant or metabolite in some of these compounds or indeed be 
simply reflective of a low potency of the parent compound itself.
CHAPTER FIVE
EFFECT OF CHLOROPHENOXYACID PRE-TREATMENT ON IN VIVO DRUG
METABOLISM IN THE RAT
CHAPTER 5
EFFECT OF CHI/)ROPHENOXYACID PRE-TREATMENT ON IN VIVO DRUG 
METABOLISM IN THE BAT
5.1 INTRODUCTION
In rat as well as in man, antipyrine is almost completely 
metabolised by hepatic cytochrome P-450, with only a few 
percent of the dose being excreted unchanged in the urine 
(Brodie and Axelrod, 1950). The excretion into urine of 
unchanged antipyrine and the three major metabolites, 4- 
hydroxyantipyrine (OHA), 3-hydroxy-methylantipyrine (HMA) and 
norantipyrine (NORA) (Fig.5.1), accounts for 65-70% of the dose 
(Darihof et al, 1979a and 1982), and has therefore been proposed 
as a probe for the drug oxidation enzymes in animals and man. 
Several groups have investigated the effects of induction of 
the cytochrome P-450 system with inducers such as phenobarbital 
and B-naphtoflavone on antipyrine metabolism patterns in rat 
urine (Danhof et al, 1979 a and b, 1982, Bottcher et al, 1982 a 
and b, Rhodes and Houston 1982, Teunissen et al, 1983) and in 
cultured rat hepatocytes (Chenery et al, 1987) and in rat liver 
microsomes (Dupont et al, 1987)in the presence of monoamine 
oxidase inhibitors. All of these authors found selective 
changes in the metabolite profile as a consequence of 
induction, suggesting that several isoenzymes of cytochrome P- 
450 metabolise antipyrine. For example, the formation of HMA is 
associated with the phenobarbital-inducible type of cytochrome 
P-450 (P-450 11A1), that of OHA with the 3-methylcholanthrene-
inducible type (P-450 1A1), while NORA is probably also formed 
by a 3-methylcholanthrene-inducible type of cytochrome P-450. 
Hence the assessment of rates of formation of antipyrine 
metabolites enables the quantitation of different drug- 
oxidizing enzymes in one test. This topic was reviewed 
recently by Poulsen and Loft (1988), Parke and Kitteringham 
(1988) and Breimer et al (1984).
Measurement of both barbiturate sleeping time and 
zoxazolamine paralysis time have frequently been used to 
distinguish between the activities of phenobarbital and 3- 
methylcholanthrene-inducible cytochrome P-450 activity 
(cytochrome P-450 IIBl and P-450 IA1 respectively) (Ioannides 
and Parke 1973, Wiebel et al 1976, Tomazewski et al 1976, 
Krevsky and Hitchcock 1977, Smith et al 1973, Graham et al 
1981, Hatanaka et al 1988a and Van der Graaff et al 1988). 
Therefore, like antipyrine, pentobarbital and zoxazolamine 
(Fig. 5.1) have been used as model substrate to study the in 
vivo drug metabolism and the influence of cytochrome P-450 
induction on its metabolism.
The aim of the study reported in this chapter was to 
assess the influence of chlorophenoxy acids treatment on the in 
vivo metabolism of antipyrine, pentobarbital and zoxazolamine 
in the rat and to correlate the
results with the induction data reported in chapter three.
Figure 5.1 The chemical sturcture of antipyrine, zoxazolamine and pentobarbital and major
metabolites
CH
ch5n\  o
N'
V
Norantipyrine
(NORA)
o
CH, oh 
c h jn\  S *0
N
3-liydroxymethylantipyri
(HMA)
4-Hydroxyantipyr\ine
(OHA)
ne
ft»5
CH*(CH2)2-CH3
H-N i  CH3
0 
Pentobarbital
6-tiydroxyzoxazolamine 
.0
H-N-
H- N-
,C*H#
W ch2chch3
CH, OH ?
Pentobarbital Alcohol
5.2 Results
5.2.1 Antipyrine metabolism
Initially I selected four compounds to study their effects 
on antipyrine metabolism: CPA, 2,4-DP, 2,4,5-T and 2,4,5-TP, 
given at 200 mg/kg/day to rats for 3 days. Treatment of
animals with 2,4,5-T and 2,4,5-TP affected their mobility in 
the cages so that their food and water intake diminished and a 
low urine excretion was noted over 24 hours and a great
decrease in body weight, necessitating that the animals were 
killed before the end of the experiment. The same effect was 
not observed with the control group or other pre-treatments. 
Urine collection was started 24 hours before antipyrine dosing 
and this was taken as a background reading to see the presence 
of peaks that may coincide with the metabolite peaks which can 
be detected by the HPLC system. Antipyrine (70 mg/kg) was 
given to the animals 24 hours after the last treatment and
urine collection started immediately for 24 hours. Sodium
pyrosulphite as an anti-oxidant was added to the urine samples 
and stored at -20°C until used for analysis.
The metabolites of antipyrine are excreted in urine mainly 
as conjugates (Bottcher et al 1982a). Therefore enzymatic 
hydrolysis with glucoronidlase-sulphatase was performed prior 
to the metabolite assay, since it resulted in complete cleavage 
of the conjugates in the presence of sodium pyro-sulphite (16
mg/ml) as an antioxident to prevent decomposition of 
metabolites.
The extraction and separation procedures were performed as 
described in methods. Evaluation of the chromatograms were 
based on peak height as calculated by the internal standard 
method (phenacetin). The identification of the peaks was based 
on the method described by Teunissen et al (1983) and the 
comparison of the chromatographic charts of urine samples 
before and after antipyrine dose (Fig. 5.2a,b). As shown in 
Fig.5.2a,b the extra peak in CPA-treated rats made it difficult 
to identify a peak corresponding to HMA.
Both compounds used (CPA and 2.4-DP-200 mg/kg/day for 3 
days) significantly increased urine volume excreted over the 24 
hours (8.5+3 and 16-7 ml compared to control 6.8 ml per 24 
hours). The effect of CPA and 2,4-DP treatment on antipyrine 
metabolism were compared to control. From Fig. 5.3, a general 
, decrease in the antipyrine metabolites detected in urine of CPA 
and 2,4-DP pre-treated rats were observed. It is clear that 
2,4-DP had the greater effect on OHA, NORA and HMA formation 
when 24 hours urine volume was taken into consideration (Fig. 
5.4). As for OHA (Fig.5.5), the availability of the compound 
enabled us to draw a standard curve and to evaluate its 
metabolism in mg excretion in urine. It is quite clear that 
there was a small decrease in OHA excreted per ml. urine when 
compared to control (91% and 80% of control after CPA and 2,4-
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DP treatment respectively), and showed a slight increase when 
adjusted to the total urine volume of 24 hours collection (114% 
and 188% of control). This is because of the increase in urine 
volume excreted in CPA and 2,4-DP treated rats.
Fig.5.4 shows the 24 hours elimination of OHA, NORA and 
HMA. It is clear that the 24 hours elimination levels differ 
from the units/ml (peak height ratio) (Fig.5.3). Only 2.4-DP 
showed a significant increase in OHA elimination in 24 hours 
urine collection, (188% of control, p 0.01) (28.6 ug/ml urine). 
Although NORA and HMA showed a slight decrease from the control 
levels, it was not found to be statistically significant due to 
the high difference in individual elimination.
5.2.2 Pentobarbital Sleeping time
A pilot experiment was done to compare the effect of 2,4- 
D, 2,4,5-T (200 mg/kg) and clofibrate (250 mg/kg) on
pentobarbital sleeping time (Fig.5.6). Rats were divided into 
groups (10 animals per group) and were treated with the 
appropriate compound for three days as described in Methods. 
Control rats were given peanut oil (5 ml/kg), pentobarbital 30 
mg/kg was administered 24 hours after the last treatment. 
Sleeping time was recorded as described in Methods. As can be 
seen in Fig.5.6, pentobarbital treatment showed a sleeping time 
of 38+9 minutes in the control group whereas 2,4-D and
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clofibrate pre-treatment significantly prolonged the sleeping 
time (142% and 129% respectively of control). It was noted 
that the 2,4-D pretreated group was not as healthy as the other 
groups and this may be a significant factor in prolonging the 
sleeping time. 2,4,5-T treatment showed no significant change 
in pentobarbital sleeping time. These results may be taken in 
comparison with the lack of induction of cytochrome P-450 IIBI 
seen in chapter 3.
5.2.3 Zoxazolamine paralysis time
Treatment of rats with zoxazolamine (70 mg/kg)(Fig.5.7), a 
muscle relaxant which causes temporary paralysis, resulted in 
92 minutes of paralysis time in the control group (average of 
10 animals). When compared to the control group 2,4-DP and
2,4,5-TP, pre-treatment significantly reduced the sleeping time 
to 67% and 48% of control respectively. It is only 2,4-D pre­
treatment which prolonged markedly the paralysis time - 44% 
over the control level.
This may suggest that 2,4-DP and 2,4,5-TP induced 
zoxazolamine metabolising enzyme (cytochrome P-450 IAI). This 
suggestion is not in line with our previous results: chapter 3 
which suggested that these compounds have no clear effect on 
the ethoxyresorufin-0-deethylase activity. One might expect 
that MCPA pre-treatment may induce zoxazolamine metabolism and
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hence shorter paralysis time, based on our previous results, 
hut that was not shown. CPA, 2,4-DB and 2,4,5-T pre-treatment 
did not show any significant effect on the zoxazolamine 
paralysis time.
5.3. Discussion
To compare the induction of in vitro drug metabolism, 
(seen in chapter 3), and in vivo drug metabolism, three
substrates commonly used to investigate drug metabolism in 
vivo, namely, antipyrine, pentobarbital, and zoxazolamine, were 
used in the present study.
Antipyrine was chosen as a convenient "prototype" drug 
which has become popular for the estimation of in vivo
cytochrome P-450 - mediated drug oxidations. Changes in the 
hepatic cytochrome P-450 system have been correlated directly
with changes in in vivo antipyrine metabolism and the
"antipyrine test" has thus been used extensively in both man 
and laboratory animals for the assessment of cytochrome P-450 
mixed function oxidase activity (Stevenson 1977, Vesell 1979, 
Danhof et al 1979a and 1982). I assessed the metabolism of 
antipyrine and the excretion of the three main metabolites of 
antipyrine in urine.
^  results demonstrate the lack of real effect on 
antipyrine metabolism by the treatment of rats with CPA and
2,4-DP (200 mg/kg), consistent with the lack of induction of 
cytochromes P-450 IA1 and P-450 IIB1 by CPA and 2,4-DP 
treatment reported previously (Figs. 3.3 & 3.4). These two 
isoenzymes of cytochrome P-450 have previously been shown to be 
involved in antipyrine metabolism leading to different 
metabolite formation (namely OHA, NORA and HMA. respectively) 
(Danhof et al 1982. Rhodes and Houston 1982, Bottcher et al 
1982 a &b).
Fig.5.5 showed a slight increase in OHA excretion in rat 
urine after 2,4-DP treatment (188% of control), coincident with 
a small decrease in paralysis time caused by zoxazolamine (Fig. 
5.7). This was not supported by a positive increase in 
microsomal ethoxyresorufin-O-deethylase activity (Fig.3.3). 
This may suggest that the small increase in cytochrome P-450 
IAI isoenzyme activity seen in the in vivo experiments is not 
significant enough and could not be detected in the liver or 
kidney microsomes. Neither NORA nor HMA was affected by CPA 
or 2,4-DP pre-treatment (Fig. 5.4). It is only OHA which we 
were able to quantitate in ug (Fig.5.5) since I had the pure 
compound and we were able to construct a standard curve.
It is known that zoxazolamine is metabolised mainly to 6- 
hydroxyzoxazolamine, and chlorzoxazone as a minor metabolite, 
by 3-methylcholanthorene induced P-450 IAL) (Tomaszewski et al 
1976. Conney at al 1960, Van der Graaff et al 1986, Yasuhara 
and Levy 1988).
My earlier results indicated a small induction of 
microsomal ethoxyresorufin-O-deethylase activity by some of the 
compounds studied in chapter 3. Therefore, I attempted to 
correlate that of microsomal enzyme activity with the in vivo 
enzyme activity by means of using zoxazolamine paralysis time. 
One may expect to see a real decrease in paralysis time mainly 
by MCPA since it was the highest inducer of ethoxyresorufin-O- 
deethylase activity (140% over control levels). On the 
contrary, MCPA showed no effect on paralysis time (zoxazolamine 
metabolism)(Fig 5.7). In contrast 2,4,5-TP showed the highest 
effect on zoxazolamine paralysis time. It reduced 
significantly the paralysis time to 40% of control (P<0.001), 
whereas 2,4-D was the only compound that increased the 
paralysis time to 145% of control. This is because of the 
effects of 2,4-D on the mobility of the animals. Other 
compounds that decreased paralysis time were 2,4-DP, 2,4,5-T 
and CPA (67%, 89% amd 87% of control respectively), when only
2,4,5-T slightly increased microsomal ethoxyresorufin-O- 
deethylase activity to 160% of control.
In summary, my results demonstrate lack of real effect of 
the chlorinated phenoxyacids studied on the hi vivo metabolism 
of the substrates used, namely, antipyrine, zoxazolamine and 
pentobarbital. Since these substrates are metabolised mainly 
by cytochrome P-450 IA1 and/or P-450 IIB1, the results 
presented here support my earlier results, suggesting that the 
compounds studied have little effect, if any, on these two
isoenzymes both in vivo and in vitro, supporting the earlier 
conclusion that chlorophenoxyacids are relatively specific 
inducers of cytochrome P-450 IVA1 isoenzyme. Thus it may be 
concluded that cytochrome P 450 IVA1 plays no role in the 
metabolism of the compoundtested; a conclusion not inconsistent 
with the narrow substrate specificity (i.e. for fatty acids) of 
this particular isoenzyme (Tamburini et al., 1984).
CHAPTER SIX
EFFECTS OF CHLOROPHENOXYACIDS AND CHLOROPHENOLS 
ON CYTOCHROME P-450 IVA1 mRNA
CHAPTER 6
EFFECTS OF CHDOROPHH«)XYACIDS AND CHLOROFHENOLS 
ON CYTOCHROME P-450 IVA1 mRNA
6.1 INTERODOCTION
In order to understand the molecular basis of cytochrome P-450 
induction and peroxisome proliferation much of the research in this 
field is concentrated on the molecular biology and the events that 
occur at the molecular level following the administration of 
peroxisome proliferators to animals and isolated cell lines.
The cytochrome P-450 IVA1 gene has been cloned from rat liver 
(Hardwick et al, 1987, Eamshaw et al, 1988), as well as the genes 
for several of the enzymes of the peroxisomal jB -oxidation spiral 
including 3-hydroxyacyl-CoA dehydrogenase bifunctional protein 
(Osumi et al, 1965, Chatterjee et al, 1987). Several groups have 
used cDNA probes to study the changes in mRNA levels following the 
administration of preroxisome proliferators to rats. These studies 
have shown that observed increases in the mRNA for cytochrome P-450
IVA1 and the bifunctional protein are due to transcriptional
activition of these genes (Osumi et al, 1985, Chatter jee et al,
1987, Hardwick et al, 1987, Milton, 1989). These increases in the
rate of transcription have been shown to occur in vivo as early as 
one hour after the administration of inducers such as clofibrate 
(Milton, 1989, Osumi et al, 1985, Hardwick et al, 1987).
In this chapter the influence of pre-treatment of rats with 
four chlorophenoxy acids and related phenols on the mRNA coding for 
cytochrome P-450 IVA1 and the bifunctional protein has been studied 
in an attempt to rationalise on a molecular level the previously 
described changes in both enzyme activity and apoprotein induction.
6.2 Results
Total hepatic RNA. was isolated from rats treated with CPA, 
MCPA, 2,4-DP, 2,4,5-TP and the related chlorophenols CP, MCP, DCP 
and TCP at 200 mg/kg/day for 3 days and from control rats (Peanut 
oil treated) by the method of Chomczynski and Sacchi (1987) as 
outlined in Chapter 2. The samples were hybridised with actin cDNA 
(as a control), the cytochrome P-450 IVA1 cDNA and the bifunctional 
enzyme cDNA probes. The cDNA. probes used in this study were either
provided as insert DNA (cytochrome P-450 IVA1 and actin) or as 
insert DNA in plasmid (bifunctional protein). A marked increase in 
the mRNA hybridising to the cytochrome P-450 IVA1 cDNA probe was 
observed in the 2,4,5-TP, 2,4-DP and MCPA treated rat (fig.6.1). 
By using densitometric analysis, I was able to compare the density 
of the RNA. dots as a percentage of the control value (fig. 6.2). 
There was a 2.7-fold increase in the level of mRNA. after 2,4,5-TP 
pretreatment and 2,4-DP and MCPA pretreatment resulted in 2.4- and 
1.8-fold increases in P-450 IVA1 mRNA, respectively. All other 
treatments showed no significant increase in the cytochrome P-450 
IVA1 in mRNA. The bifunctional protein mRNA level showed a similar 
pattern of increase as that of cytochrome P-450 IVA1 mRNA level
Figure 6.1 Influence of phenoxy acid and phenol pretreatment 
on the levels of cytochrome P--450IVA1 mRNA in rat
liver.
ug total RNA / dot
O  *1
“ ats were pretreated with phenoxy acids (CPA, 2,4,5-TP, 2,4-DP and MCPA) 
nd phenols ( CP, TCP, DCP, and MCP ) at a dose of 200 mg/kg/day for 
days and RNA was extracted from the liver as described in methods.
ZNA dot blot was performed as described in methods. A plasmid of 2.1 kbp 
as used to hybridise the specific cytochrome P-450IVA1 mRNA.
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after 2,4-DP, 2,4,5-TP and MCPA treatment (data not shown). There 
was no change in the level of actin mRNA throughout the different 
samples (data not shown). The level of actin mRNA serves as a 
positive control for the hybridization analysis, as its expression 
is not affected and can be used to show that there has not been a 
general, non-specific, increase in mRNA production and that 
equivalent amounts of RNA have been loaded per dot. The increase 
in cytochrome P-450 IVA1 mRNA is in accordance with the increases 
seen in cytochrome P-450 IVA1 apoprotein and lauric acid w- 
hydroxylase activity (reproduced in fig. 6.3 and 6.4) and the 
detailed results reported in Chapters 3 and 4.
Chlorinated phenoxy acid pre-treatment also showed a 
significant increase in cyanide-insensitive pahnitoyl-CoA oxidation 
of the peroxisomal /^-oxidation pathway (reproduced in fig. 6.5) 
whereas, the related chlorophenols, showed no change in the enzyme 
activity, a pattern similar to that of cytochrome P-450 IVA1 and 
laurate 12-hydroxylase induction (fig. 6.3 and 6.4). Furthermore,
2,4,5-TP was the most potent inducer of the different enzyme 
activities studied as well as for the mRNA coding for cytochrome P- 
450 IVA1 and the bifunctional enzyme.
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6.3 Discussion
The data presented in this chapter demonstrates a good 
relation between the induction of cytochrome P-450 IVA1 and 
palmitoyl-CoA oxidase in regard to the different compounds studied. 
It is clear from fig. 6.3 - 6.5 that the most potent inducer of the 
specific content of cytochrome P-450 IVA1 and laurate 12-hydroxylase 
(2,4,5-TP) (4-fold and 7-fold respectively) is also the most potent 
inducer of peroxisomal ^-oxidation (3-fold) as indicated by the 
induction of palmitoyl-CoA oxidation. This increase in the enzyme 
activity is accompanied by an increase in cytochrome P-450 IVA1 mRNA 
(fig. 6.1) and the bifunctional protein mRNA (data not shown, due to 
technical difficulties). These findings and the previous results 
reported in Chapter 3 for the chlorophenoxy acid herbicides are 
comparable to results reported by Sharma (1988) and Milton (1989) 
using clofibrate and related hypolipidaemic drugs.
The bifunctional protein of peroxisomes from rat liver 
expresses both the enoyl-CoA hydratase and 3-hydroxyacyl-CoA 
dehydrogenase enzyme activities which form part of the fatty acid P- 
oxidation pathway in peroxisomes (Osumi and Hasimoto, 1979). In 
peroxisomes, the activities of enoyl-CoA hydratase and 3- 
hydroxyacyl-CoA dehyrogenase have been shown to copurify on one 
single polypeptide of molecular weight 80,000 dal tons whereas in 
mitochondria the enzyme activities reside on separate protein 
molecules (Boemer and Osumundsen, 1984). The protein was markedly 
induced in peroxisomes following treatment of rodents with
peroxisome proliferators such as clofibrate (Reddy et al, 1980, 
Makoswka, 1988).
Recently, Chat ter jee et al, (1987) demonstrated that the 
treatment of hepatocytes in culture with Wy-14,643 resulted in an 
increase in the peroxisomal bifunctional enzyme. It was concluded 
that the induction of the peroxisomal bifunctional enzyme by Wy- 
14,643 in hepatocytes is due to an increase in the rate of 
transcription of the enzyme gene and so increase in the enzyme mRNA 
(Chat ter jee et al, 1987). This induction of the bifunctional
enzyme mRNA in hepatocytes was shown to take between 10-15 hr after
Wy-14,643 treatment. In the intact rat, it was shown that this 
compound increased the hepatic bifunctional enzyme mRNA within 1 hr 
of treatment (Reddy et al, 1986). This is similar to a recent 
result in this laboratory where the induction of the bifunctional
enzyme mRNA by clofibrate was shown to be detectable in rat liver
shortly (approximately one hour) after a single clofibrate dose 
(Milton, 1989). Furthermore, this increase was preceded by an 
increase in the cytochrome P-450 IVA1 mRNA in a time dependent 
manner. Milton (1989) showed that there was a biphasic response in 
the cytochrome P-450 IVA1 mRNA levels in rat liver after a single 
i.p. dose of sodium clofibrate and that the bifunctional protein 
mRNA appeared later than the earlier burst of cytochrome P-450 IVA1 
mRNA increase. Similarly, there was a dose and time dependent 
increase in the enzymes of ^-oxidation and cytochrome P-450 IVA1, 
and the increase in the latter enzyme preceded the enzymes of /®- 
oxidation in a time dependent manner (Sharma, 1988, Milton, 1989).
This lead to a proposed scheme suggesting that the induction of 
cytochrome P-450 IVA1 precedes the induction of ^ -oxidation at the 
enzymatic and molecular level (Sharma et al, 1988 a). This scheme 
has additionally been verified on in vitro experiments in cell 
culture, using both mono- and dicarboxylic fatty acids, and on the 
relationship of the enzyme activities involved (C.R.Elconibe, 
Personal Communication). The data presented in this thesis for the 
chlorephenoxy acids are not inconsistent with this scheme, which is 
presented in Chapter 1.
In conclusion, my results have demonstrated that there is a 
close association between the induction of cytochrome P-450 IVA1 and 
its mRNA, its associated laurate 12-hydroxylase activity and the 
peroxisomal fatty acid ^ -oxidation pathway. Although no attempt was 
made to identify structure-induction relationships, my results have 
clearly shown that there is a potency order of induction since
2,4,5-TP > 2,4-DP > MCPA > CPA in inducing the various parameters 
studied.
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DISCUSSION
For drug design it is important to understand structure 
activity relationships and toxicology studies.. Many workers 
havestudied the structure activity relation of peroxisome 
proliferators in rodents (Katoh et al., 1984; Foumel et al., 1985; 
Lundgren et al., 1987a, b, 1988; Sharma et al., 1988a). It appears 
that the blocking of the -carbon atom such as clofibric acid,
2,4,DP and 2,4,5-TP results in more potent induction of peroxisomal 
^-oxidation. My results support such a proposal in regard to 
cytochrome P-450 IVA1 induction since 2,4,5-TP (among the seven 
compounds studied) showed the highest induction level of this enzyme 
at the protein and molecular level. CPA, being the smaller of the 
compounds, showed the least induction capacity. The positioning of 
the chlorine atoms on the phenyl ring is also of importance since
2,4,5-TP > 2,4-DP and 2,4,5-T > 2,4-D > CPA induces cytochrome P-450 
IVA1 or ^ -oxidation enzyme activities. However, the effect of the 
blocked carbon atom, and position of and extent of chlorination of 
the phenyl ring, is not as simple as it first seems as 2,4-DB 
appears to be less potent than 2,4-DP or 2,4-D. This is in contrast 
to the effect of the substitution of the Cf- -carbon atom on the 
induction of peroxisomal jB-oxidation suggested by Katoh et al 
(1984), and serves to highlight the interactive nature of the 
structural elements of the peroxisome proliferators including 
chlorophenoxyacids. This is inconsistent with the proposal that all 
these compounds appear to consist of a carboxylic function carried 
on a hydrophobic backbone to yield an amphipathic carboxylate (Hertz
et al., 1988). The carboxylic function may either be present 
initially, as in the case of clofibric acid and related drugs and 
chlorophenoxyacids, or may be derived by metabolic oxidation via the 
respective alcohols. The free carboxylic acid function, or a 
derivative thereof, is presumably directly involved in the induction 
process, whilst the nature of the hydrophobic backbone may determine 
the potency of the compound. To shed some light on the importance 
of the carboxylic acid group, my results using chlorinated phenols 
(related to chlorophenoxy acids) showed no significant potency in 
inducing cytochrome P-450 IVA1 or peroxisomal ^ -oxidation. It is 
possible that chlorphenols, like phenol, are actively metabolised by 
Phase II conjugation enzymes (Dodgson, 1977; Bruce et al., 1987), 
thus rapidly removing the inductive stimulus. Further structure- 
activity relationship analysis may help us define which parameters 
are important for peroxisome proliferation and/or hypolipidaemic 
activity.
My results have shown that all of the chlorophenoxy acids 
studied increased the activity of lauric acid 12-hydroxylation 
(Fig.3.5) accompanied by increase in the cytochrome P-450 IVA1 
protein (Table 3.1). Furthermore, 2,4,5-TP, 2,4-DP and MCPA
significantly increased the levels of cytochrome P-450 IVA1 mRNA. 
This, with the other results which showed that the enzyme activities 
of benzphetamine-N-demethylase and ethoxyresorufin-O-deethylase 
(substrates for cytochrome P-450 IIBl and P-450 IA1 respectively) 
were not significantly changed by some of the compounds after 
treatment, suggest that the cytochrome P-450 IVA1, P-450 IIBl and P-
450 IA1 isoenzymes are differentially regulated by corresponding 
inducers, a conclusion that is consistent with the available 
literature (Hardwick et al., 1987, Nebert et al., 1987). This 
observation is also in support of the suggestion that the genes 
coding for the cytochrome P-450 isoenzymes can be regulated in 
several different ways (Nebert and Gonzalez, 1985; Adesnik and 
Atchison, 1985; Whitlock, 1986; Gonzalez, 1989). The most studied 
isoenzyme of cytochromes P-450 is cytochrome P-450 IA1 and IA2 which 
have been shown to be regulated by a soluble intracellular protein 
receptor which binds specific aromatic hydrocarbons such as 3- 
methylcholanthrene and dioxines such as TCDD (Okey and Vella, 1982; 
Poellinger et al., 1983; Welhelmsson et al., 1986; Durrin et al.,
1987), and is termed the Ah receptor. There is evidence that these 
latter isoenzymes may be regulated by increasing the rate of 
transcription (and decreasing cytochrome P-450 IA mRNA degradation) 
following the binding of the inducing agent, such as TCDD (Israel 
and Whitlock, 1984; Gonzalez and Nebert, 1985). It is also possible 
that the regulation of these isoenzymes may involve a distinct 4S 
trans-regulatory protein (Houser et al., 1985; Bresnick et al.,
1988) and/or post-transcriptional regulation (Pasco et al., 1988; 
Silver and Krauter, 1988). Recently Foldes and Bresnick (1989) have 
demonstrated, (by using 3-MC and cycloheximide to study the 
inducibility of cytochrome P-450 IA1 mRNA in rat liver), the 
existence of a specific labile repressor of cytochrome P-450 IA1 
gene expression in vivo. However, the precise details of this 
trans-regulatory mechanism remain to be fully elucidated. The 
mechanism(s) of induction of cytochromes P-450 IIBl and P-450 IIB2
and P-450 IVA1 is still far from clear. Evidence for cytosolic 
receptor involved in the induction of these isoenzymes is still 
debatable (Fonne and Mayer, 1987; Milton et al., 1988).
Furthermore, Milton (1989) showed that there was no protein 
dependency for the induction of cytochrome P-450 IVA1 mRNA., thereby 
excluding the intermediacy of a labile, regulatory protein in the 
induction process.
A scheme was proposed by Sharma et al., (1988a) (Fig. 1.1), 
whereby xenobiotics can perturb hepatic lipid homeostasis by 
interacting with the enzymes of fatty acid metabolism, thereby 
causing a lipid overload. It has been suggested that the stimulus 
for the induction of peroxisomal JB-oxidation is long-chain 
dicarboxylic fatty acids formed initially by the w-hydroxylation of 
the corresponding monocarboxylic fatty acids by cytochrome P-450 
IVA1 and subsequent oxidation of the proximal peroxisomal 
proliferator, namely the decarboxylic acid metabolite. The 
induction of cytochrome P-450 IVA1 is postulated to occur before the 
induction of peroxisomal yB-oxidation. Support for this scheme came 
from the results of Milton (1989) which showed that cytochrome P- 
450 IVA1 was induced before peroxisomal >B-oxidation although the 
events do appear to be closely related temporally. It may be 
possible that the signal for the induction of peroxisomal >B- 
oxidation may be generated in part by constitutive cytochrome P-450 
IVA1. This may mean that the induction of cytochrome P-450 IVA1 and 
peroxisomal yB-oxidation, although distinct events, may be closely 
related temporally. The co-induction of the microsomal fatty acid
hydroxylase and the peroxisomal yB-oxidation system (the latter being 
indicated by the induction of palmitoyl-CoA oxidation) may be the 
result of disturbances in the metabolism of lipids (Cappuzi et al., 
1983; Mitchell and Hinton * 1988). Following clofibrate treatment 
there is an accumulation of lipid in the liver in a similar fashion 
to that observed in animals receiving high fat diets (Neat et al., 
1981).The way in which this lipid overload causes the observed 
increased rates of gene transcription is unknown although it is 
possible that cellular second messenger systems are involved, a 
possibility being actively pursued in this laboratory.
Much of the current research on the molecular biology of the 
cytochrome P-450 system is concerned with the elucidation of the 
genetic and molecular mechanisms responsible for the existence of a 
multiplicity of forms of cytochrome P-450 and also for the induction 
of distinct forms by specific inducing agents (Adesnik and Atchison, 
1986). Using an antibody to clofibrate inducible cytochrome P-450 
IVA1, the isoenzyme was immunochemically detected in non-induced rat 
liver and kidney microsomes (Tamburini et al., 1984; Bains et al., 
1985). The level of this isoenzyme was markedly elevated after 
clofibrate treatment due to an activation of cytochrome P-450 IVA1 
mRNA synthesis as determined using the corresponding cDNA probe 
(Hardwick et al., 1987).This rapid transcriptional increase is
similar to the transcriptional activation of fatty acyl-CoA oxidase 
and enoyl-CoA hydratase/3-hydroxy acyl-CoA dehydrogenase induced by 
clofibrate in rat liver (Reddy et al., 1986; Milton, 1989). It 
appears that cytochrome P-450 IVA1 is regulated by the same 
mechanism that regulates these peroxisomal enzymes, and may form a
battery of genes that are co-regulated by clofibrate and its 
structural analogues. Recently in our laboratory, a lKbp cDNA probe 
to cytochrome P-450 IVA1 was isolated from a clofibrate-induced rat 
liver cDNA library in the bacteriophage expression vector Lamda gtll 
using anti-cytochrome P-450 IVA1 sera and a biotin-streptavidin 
linked immunoassay (Eamshaw et al., 1988) .This cDNA probe as well 
as a 2.1Kbp cDNA. probe to cytochrome P-450 IVA1 are being used in 
our laboratory to examine the corresponding mRNA levels in untreated 
and treated animals utilising hybridisation methodology.
Induction of cytochrome P-450IVA1 by peroxisome proliferators 
exhibited a negative correlation when compared to benzphetamine-N- 
demethylase and ethoxyresorufin-O-deethylase activities indicating a 
specific gene switch-off for these two activities (Gibson and 
Sharma, 1987). My results are in support of these suggestions since 
a poor correlation was seen between the enzymes indicated above 
following 2,4,5-TP pretreatment (Table 3.3). Furthermore, there was 
a positive correlation between cytochrome P-450 IVA1 and laurate 12- 
hydroxylation and total cytochrome P-450 with all of the 
chlorophenoxy acids with the exception of 2,4-DB and CPA (Table 
3.2).
The lack of real induction in benzphetamine-N-demethylase and 
ethoxyresorufin-O-deethylase activities is exemplified also by the 
in vivo results in chapter 5 where there was no real induction in 
the metabolism of pentobarbital or zoxazolamine except for marginal 
increases by some of the compounds studied. Furthermore, the
increase in antipyrine metabolism to 4-hydroxyantipyrine after 2,4- 
DP pre-treatment needs to be further investigated using other 
compounds since formation of this metabolite can be influenced by 
phenobarbital and 3-methylcholanthrene (Danhof et al., 1979;
Teunissen et al., 1983; Buppodom et al., 1986; Chenery et al., 1987; 
Loft and Poulsen, 1989).
Imaoka and Funae (1986) have reported the isolation of the 
major cytochrome P-450 isoenzyme from kidneys of untreated rats. 
This protein was shown to catalyse the w- and (w-l)-hydroxylation of 
lauric acid and its monomeric molecular weight was determined by 
SDS-PAGE to be 52,000 Da. This would correspond to the upper band 
in clofibrate-treated kidney microsomes reported by (Sharma 1988) as 
visualised by Western blotting. This upper band may represent the 
active laurate hydroxylation in kidney microsomes with which 
although recognised by the polyclonal anti-cytochrome P-450 IVA in 
an inhibition study (Sharma, 1988), is sufficiently distinct so that 
its catalytic activity is uninhibited.
The high basal level of cytochrome P-450 IVA1 in rat kidney 
suggests that this enzyme represents a major form of cytochrome P- 
450 in rat kidney. This is supported by measurement of 
benzphetamine and ethoxyresorufin dealkylation activities (Table 
3.4), the latter two enzymes are generally being accepted as good 
markers for the cytochrome P-450 IIB1 and P-450 IA1 isoenzyme 
respectively. These two isoenzymes activity were 10-fold lower than 
that seen in hepatic microsomes. These results are supported by the
results of Hardwick et al., (1987) who reported that in non-treated 
animals cytochrome P-450 IVA1 was readily detectable in rat kidney, 
whereas cytochrome P-450 IA1 and 2, and P-450 IIB1 and 2 were 
undetectable.
There is much debate at present on whether the carcinogenicity 
and/or peroxisomal proliferative activity induced in rats by 
realistic exposure doses of certain widely used compounds is, in 
fact, likely to constitute a problem for man when exposed to these 
substances. Acute toxicity in rats following exposure to a variety 
of xenobiotics may result in carcinogenicity. With the 
administration of peroxisome proliferators, enzyme induction occurs 
but this is not related to gross toxicity. However, 
hepatocarcinogenesis develops in treated rats between 1 and 2 years 
(Reddy and Lalwani, 1983). These compounds, including 
chlorophenoxyacids, are uniformly negative in a wide range of 
mutagenicity tests indicating a class of non-genotoxic carcinogens. 
No binding of clofibrate nor its metabolites and related drugs to 
hepatic nuclear DNA has been detected (Von Dankin et al., 1981) and 
nafenopin and Wy-14,643 exhibited no significant binding to DNA in 
vitro or in vivo (Goel et al., 1985) and no peroxisome proliferator 
DNA. adducts were detected in hepatocytes under in vivo and in vitro 
conditions with clofibrate and other peroxisome proliferators (Gupta 
et al., 1985).
In order to explain the carcinogenicity of peroxisome 
proliferators in rodents, it has been suggested that the marked
increase in peroxisomal /3-oxidation leads to an excessive production 
of hydrogen peroxide by fatty acyl-CoA oxidase (Reddy and Lalwani, 
1983; Elliot et al., 1986). It has also been suggested that 
stimulated peroxisomes may be leaky and that excessive hydrogen 
peroxide may diffuse into the cytoplasm of the cell. The hydrogen 
peroxide may interact with a non-DNA target producing active oxygen 
species. The active oxygen species may cause lipid peroxidation,
DNA. attack and hepatocarcinogenesis. Consistent with this lipid 
peroxidation proposal of neoplastic transformation is the observed 
accumulation of lipofuscin in the livers of treated rats (Reddy et 
al., 1982).This is supported by the results of Makowska (1988) and 
Sharma (1988) which showed that the specific activity of catalase 
was unchanged by treatment with hypolipidaemic drugs (total activity 
was increased in parallel with hepatomegaly) and this may be 
insufficient to remove excessive hydrogen peroxide produced in 
stimulated peroxisomes. In long-term studies (26 weeks) with 
bezafibrate and ciprofibrate, the specific activity of catalase was 
significantly decreased (Makowska 1988). Furthermore, there was a 
fifty percent decrease in hepatic glutathione peroxidase activity 
observed with ciprofibrate treatment which may potentiate oxidative 
stress by inadequate removal of cytosolic hydrogen peroxide 
(Makowska, 1988). A similar result was shown earlier using 
chlorophenoxy acids, such as CPA 2,4-D, 2,4,5-T and MCPA, indicating 
that these compounds have a similar induction pattern as that of 
clofibric acid in rat and mouse (with less magnitude) (Kawashima et 
al., 1984a,b; Vainio et al., 1983; Hietanin et al., 1985; Vessey and 
Boyer, 1984; Lundgren et al., 1987a,b). These results showed that
the chlorophenoxy acid compounds induce several enzymes including 
the enzymes of hepatic ^ B-oxidation and peroxisomal proliferation as 
with catalase, glutathione reductase, glutathione peroxidase, 
gluthathione S-transferase and epoxide hydrolase. These studies 
suggest that the cytotoxicity and hepatocarcinogenicity (if any) of 
these compounds may be of similar mechanism to that of the more 
studied group of compounds such as the hypolipidaemic drugs 
including clofibrate. Under physiological conditions, the hydrogen 
peroxide produced in peroxisomes is largely disposed of by catalase 
whereas hydrogen peroxide arising from mitochondria, endoplasmic 
reticulum or cytosolic enzymes such as superoxide dismutase, is 
acted upon by glutathione peroxase (Halliwell and Gutteridge, 1985).
Hydrogen peroxide may also be produced in the endoplasmic 
reticulum by the uncoupling of cytochrome P-450 mixed function 
oxidase activity. Metabolic pathways involving cytochrome P-450 
enzymes may initiate or modulate oxidative damage due to oxygen 
radicals (Gonder et al., 1988). In mice oxygen toxicity has been 
shown to parallel the genetic control of cytochrome P-450 enzyme 
induction and toxicity developed at a time when the cytochrome P-450 
enzyme system was induced by oxygen. With clofibrate administration 
microsomal and cytosolic epoxide hydrolases were induced and this 
may be a protective mechanism (Moody et al., 1985) •
The research presented in this thesis has shown that the 
chlorophenoxy acids studied have a similar pattern of enzyme 
induction in Wistar albino rats as that of clofibrate and related
drugs. Furthermore, the vivo and in vitro studies reported 
indicate that this class of compounds are selective in inducing 
cytochrome P-450 IVA1 and not cytochrome P-450 IA(1 and 2) or 
cytochrome P-450 IIB(1 and 2); a conclusion supported by research in 
this laboratory using a large number of hypolipidaemic drugs.
OUTLOOK
The evaluation of the safety of chemicals in man is based 
largely upon the extrapolation of animal data to predict the 
likelihood of toxicity. Detailed knowledge of the pharmacodynamic 
and pharmacokinetic profiles of the compound both in man and animals 
is required.
The expression of fatty acid metabolising enzymes in rat liver 
is dependent upon the inductive and suppressive effects of various 
endogenous and exogenous substances such as clofibrate, the related 
chlorophenoxy acid and constitutive fatty acids. It is of 
importance to study and to understand the nature and the mechanism 
by which these compounds exert their effect. In this context our 
laboratory, using cDNA probes to cytochrome P-450 IVA1, fatty acyl- 
CoA oxidase, peroxisomal bifunctional protein and glutathione 
peroxidase, is studying the molecular expression and regulation of 
these enzymes. The role of cytochrome P-450 IVA1 in vivo in normal 
physiological processes and the existence of high levels of this
enzyme in kidney, need to be further studied. More studies are also 
required to further understand the nature and relationship between 
induced peroxisome proliferation and hepatocarcinoma.
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